https://it.psychopharmacologyinstitute.com/section/tendenze-nell-uso-di-farmaci-psicotropi-negli-anziani-it/ 2026-09-01T16:34:54+00:00 https://it.psychopharmacologyinstitute.com/section/modificazioni-farmacologiche-correlate-all-eta-considerazioni-negli-anziani-it/ 2026-09-01T16:34:58+00:00 https://it.psychopharmacologyinstitute.com/section/sfide-nella-prescrizione-di-psicofarmaci-nella-popolazione-geriatrica-it/ 2026-09-01T16:35:01+00:00 https://it.psychopharmacologyinstitute.com/section/considerazioni-su-ssri-e-snri-negli-anziani-dosaggio-effetti-collaterali-e-monitoraggio-it/ 2026-09-01T16:35:04+00:00 https://it.psychopharmacologyinstitute.com/section/prescrizione-di-mirtazapina-bupropione-tca-e-maoi-nella-popolazione-geriatrica-it/ 2026-09-01T16:35:08+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-di-potenziamento-e-ect-nella-depressione-geriatrica-it/ 2026-09-01T16:35:12+00:00 https://it.psychopharmacologyinstitute.com/section/stabilizzatori-dell-umore-negli-anziani-litio-acido-valproico-e-agenti-alternativi-it/ 2026-09-01T16:35:16+00:00 https://it.psychopharmacologyinstitute.com/section/prescrizione-di-antipsicotici-negli-anziani-considerazioni-cliniche-it/ 2026-09-01T16:35:20+00:00 https://it.psychopharmacologyinstitute.com/section/benzodiazepine-e-bra-negli-anziani-considerazioni-cliniche-it/ 2026-09-01T16:35:24+00:00 https://it.psychopharmacologyinstitute.com/section/farmacoterapia-della-demenza-dagli-inibitori-della-colinesterasi-alle-terapie-anti-amiloide-it/ 2026-09-01T16:35:27+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9611-it/ 2026-09-01T16:35:31+00:00 https://it.psychopharmacologyinstitute.com/section/algoritmo-di-psicofarmacologia-per-il-ptsd-introduzione-e-panoramica-it/ 2026-09-01T16:35:39+00:00 https://it.psychopharmacologyinstitute.com/section/ptsd-situazioni-speciali-uso-di-sostanze-disturbo-bipolare-psicosi-e-gravidanza-it/ 2026-09-01T16:35:43+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-dei-disturbi-del-sonno-nel-ptsd-incubi-risvegli-e-terrori-notturni-it/ 2026-09-01T16:35:46+00:00 https://it.psychopharmacologyinstitute.com/section/prazosina-per-gli-incubi-nel-ptsd-protocolli-di-dosaggio-per-uomini-e-donne-it/ 2026-09-01T16:35:51+00:00 https://it.psychopharmacologyinstitute.com/section/inizio-del-sonno-nel-ptsd-idrossizina-trazodone-e-clonidina-it/ 2026-09-01T16:35:55+00:00 https://it.psychopharmacologyinstitute.com/section/quetiapina-benzodiazepine-e-triciclici-perche-evitarli-per-i-disturbi-del-sonno-nel-ptsd-it/ 2026-09-01T16:35:59+00:00 https://it.psychopharmacologyinstitute.com/section/selezione-di-un-ssri-per-il-ptsd-sertralina-paroxetina-ed-escitalopram-it/ 2026-09-01T16:36:03+00:00 https://it.psychopharmacologyinstitute.com/section/antipsicotici-per-il-ptsd-con-sintomi-psicotici-risperidone-aripiprazolo-e-quetiapina-it/ 2026-09-01T16:36:07+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-di-seconda-linea-del-ptsd-venlafaxina-duloxetina-e-mirtazapina-it/ 2026-09-01T16:36:11+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-di-terza-linea-per-il-ptsd-prazosina-diurna-e-clonidina-per-l-iperattivazione-it/ 2026-09-01T16:36:15+00:00 https://it.psychopharmacologyinstitute.com/section/ptsd-resistente-al-trattamento-topiramato-antipsicotici-e-opzioni-di-augmentazione-it/ 2026-09-01T16:36:19+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-10912-it/ 2026-09-01T16:36:23+00:00 https://it.psychopharmacologyinstitute.com/section/introduzione-alla-clozapina-indicazioni-ed-effetti-avversi-comuni/ 2026-09-01T16:36:32+00:00 https://it.psychopharmacologyinstitute.com/section/utilizzo-di-clozapina-per-psicosi-e-disturbi-dellumore-resistenti-al-trattamento/ 2026-09-01T16:36:35+00:00 https://it.psychopharmacologyinstitute.com/section/utilizzo-della-clozapina-per-il-rischio-di-suicidio-e-laggressivita/ 2026-09-01T16:36:39+00:00 https://it.psychopharmacologyinstitute.com/section/indicazioni-fuori-indicazione-per-la-clozapina/ 2026-09-01T16:36:43+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-pre-trattamento-e-consenso-alluso-della-clozapina/ 2026-09-01T16:36:47+00:00 https://it.psychopharmacologyinstitute.com/section/avvio-e-ottimizzazione-della-clozapina/ 2026-09-01T16:36:51+00:00 https://it.psychopharmacologyinstitute.com/section/monitoraggio-della-clozapina-sistema-rems/ 2026-09-01T16:36:55+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-della-febbre-e-degli-effetti-avversi-ematologici-della-clozapina/ 2026-09-01T16:36:59+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-degli-effetti-avversi-cardiaci-e-metabolici-della-clozapina/ 2026-09-01T16:37:03+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-di-altri-effetti-avversi-comuni-della-clozapina-2/ 2026-09-01T16:37:07+00:00 https://it.psychopharmacologyinstitute.com/section/vignetta-clinica-gestione-degli-effetti-collaterali-durante-la-titolazione-di-clozapina-2/ 2026-09-01T16:37:12+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-6/ 2026-09-01T16:37:15+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-la-risposta-psicologica-al-cancro/ 2026-09-01T16:37:24+00:00 https://it.psychopharmacologyinstitute.com/section/disturbi-depressivi-e-rischio-di-suicidio-nei-pazienti-con-cancro/ 2026-09-01T16:37:28+00:00 https://it.psychopharmacologyinstitute.com/section/fare-la-diagnosi-giusta-depressione-vs-dolore-e-demoralizzazione/ 2026-09-01T16:37:32+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-dei-disturbi-depressivi-nei-pazienti-con-cancro/ 2026-09-01T16:37:36+00:00 https://it.psychopharmacologyinstitute.com/section/disturbi-dansia-nei-pazienti-con-cancro/ 2026-09-01T16:37:40+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-dei-disturbi-dansia-nei-pazienti-con-cancro/ 2026-09-01T16:37:44+00:00 https://it.psychopharmacologyinstitute.com/section/delirium-una-complicanza-neuropsichiatrica-nei-pazienti-con-cancro/ 2026-09-01T16:37:48+00:00 https://it.psychopharmacologyinstitute.com/section/il-delirium-nei-pazienti-con-cancro-diagnosi-e-implicazioni/ 2026-09-01T16:37:52+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-del-delirium-nei-pazienti-affetti-da-cancro/ 2026-09-01T16:37:55+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-del-delirium-nei-pazienti-con-cancro/ 2026-09-01T16:37:59+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-4/ 2026-09-01T16:38:03+00:00 https://it.psychopharmacologyinstitute.com/section/un-caso-clinico-i-criteri-del-dsm-5-lepidemiologia-e-il-decorso-dei-disturbi-da-tic/ 2026-09-01T16:38:11+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-i-disturbi-da-tic/ 2026-09-01T16:38:16+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-e-screening-dei-sintomi-di-tic/ 2026-09-01T16:38:19+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosi-differenziale-per-i-disturbi-da-tic/ 2026-09-01T16:38:23+00:00 https://it.psychopharmacologyinstitute.com/section/disturbi-da-tic-e-comorbidita-psichiatriche/ 2026-09-01T16:38:27+00:00 https://it.psychopharmacologyinstitute.com/section/panoramica-del-trattamento-dei-disturbi-da-tic/ 2026-09-01T16:38:32+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-farmacologici-primari-per-i-tic/ 2026-09-01T16:38:35+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-farmacologici-secondari/ 2026-09-01T16:38:39+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-farmacologico-terziario-per-i-tic/ 2026-09-01T16:38:43+00:00 https://it.psychopharmacologyinstitute.com/section/ottimizzazione-del-trattamento-dei-disturbi-da-tic/ 2026-09-01T16:38:47+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-alternativi-e-sperimentali-per-i-disturbi-da-tic/ 2026-09-01T16:38:51+00:00 https://it.psychopharmacologyinstitute.com/section/risoluzione-del-caso-clinico-e-suggerimenti-per-i-clinici-che-trattano-i-disturbi-da-tic/ 2026-09-01T16:38:55+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-3/ 2026-09-01T16:38:58+00:00 https://it.psychopharmacologyinstitute.com/section/introduzione-ai-disturbi-del-movimento-indotti-da-farmaci-it/ 2026-09-01T16:39:06+00:00 https://it.psychopharmacologyinstitute.com/section/acatisia-come-diagnosticare-e-gestire-it/ 2026-09-01T16:39:10+00:00 https://it.psychopharmacologyinstitute.com/section/sintomi-extrapiramidali-suggerimenti-per-la-valutazione-it/ 2026-09-01T16:39:15+00:00 https://it.psychopharmacologyinstitute.com/section/tremore-indotto-da-psicofarmaci-diagnosi-e-gestione-it/ 2026-09-01T16:39:19+00:00 https://it.psychopharmacologyinstitute.com/section/sintomi-extrapiramidali-fattori-di-rischio-legati-al-farmaco-e-al-paziente-it/ 2026-09-01T16:39:24+00:00 https://it.psychopharmacologyinstitute.com/section/sintomi-extrapiramidali-strategie-di-gestione-it/ 2026-09-01T16:39:28+00:00 https://it.psychopharmacologyinstitute.com/section/discinesia-tardiva-caratteristiche-cliniche-epidemiologia-e-meccanismi-it/ 2026-09-01T16:39:33+00:00 https://it.psychopharmacologyinstitute.com/section/discinesia-tardiva-gerarchia-del-trattamento-it/ 2026-09-01T16:39:37+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-gli-effetti-collaterali-neurocognitivi-dei-farmaci-psicotropi-it/ 2026-09-01T16:39:41+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9710-it/ 2026-09-01T16:39:45+00:00 https://it.psychopharmacologyinstitute.com/section/comprensione-della-menopausa-definizioni-cliniche-e-panoramica-dei-sintomi-it/ 2026-09-01T16:39:53+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-perimenopausale-presentazione-clinica-e-meccanismi-neurobiologici-it/ 2026-09-01T16:39:57+00:00 https://it.psychopharmacologyinstitute.com/section/identificazione-dei-fattori-di-rischio-per-la-depressione-perimenopausale-it/ 2026-09-01T16:40:01+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-per-la-depressione-perimenopausale-it/ 2026-09-01T16:40:06+00:00 https://it.psychopharmacologyinstitute.com/section/terapia-ormonale-della-menopausa-mht-per-la-depressione-perimenopausale-it/ 2026-09-01T16:40:10+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-dei-sintomi-vasomotori-svms-della-menopausa-evidenze-per-ssri-snri-e-tcc-it/ 2026-09-01T16:40:14+00:00 https://it.psychopharmacologyinstitute.com/section/ansia-perimenopausale-distinguere-le-vampate-di-calore-dagli-attacchi-di-panico-e-il-ruolo-dell-allopregnanolone-it/ 2026-09-01T16:40:18+00:00 https://it.psychopharmacologyinstitute.com/section/ansia-perimenopausale-gestione-farmacologica-it/ 2026-09-01T16:40:22+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9509-it/ 2026-09-01T16:40:27+00:00 https://it.psychopharmacologyinstitute.com/section/esplorare-le-tendenze-emergenti-della-mortalita-materna/ 2026-09-01T16:40:35+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-diagnosi-differenziale-delle-sindromi-dellumore-post-partum-2/ 2026-09-01T16:40:39+00:00 https://it.psychopharmacologyinstitute.com/section/distinguere-il-postpartum-blues-dalla-depressione-postpartum/ 2026-09-01T16:40:43+00:00 https://it.psychopharmacologyinstitute.com/section/psicosi-post-partum-identificazione-e-valutazione-di-unemergenza-psichiatrica-2/ 2026-09-01T16:40:46+00:00 https://it.psychopharmacologyinstitute.com/section/distinguere-il-doc-post-partum-dalla-psicosi-post-partum/ 2026-09-01T16:40:51+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-riconoscere-e-gestire-la-depressione-post-partum/ 2026-09-01T16:40:55+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-della-depressione-post-partum-strategie-non-farmacologiche/ 2026-09-01T16:40:59+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-post-partum-considerazioni-farmacologiche-per-le-madri-che-allattano-al-seno/ 2026-09-01T16:41:03+00:00 https://it.psychopharmacologyinstitute.com/section/tms-e-tec-trattamenti-efficaci-per-i-disturbi-dellumore-post-partum/ 2026-09-01T16:41:06+00:00 https://it.psychopharmacologyinstitute.com/section/il-ruolo-del-brexanolone-e-dello-zuranolone-nella-depressione-post-partum-2/ 2026-09-01T16:41:10+00:00 https://it.psychopharmacologyinstitute.com/section/psicosi-post-partum-strategie-farmacologiche-2/ 2026-09-01T16:41:15+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-13/ 2026-09-01T16:41:19+00:00 https://it.psychopharmacologyinstitute.com/section/comprensione-e-diagnosi-del-disturbo-ossessivo-compulsivo-resistente-al-trattamento-it/ 2026-09-01T16:41:28+00:00 https://it.psychopharmacologyinstitute.com/section/panoramica-delle-strategie-terapeutiche-per-il-doc-it/ 2026-09-01T16:41:32+00:00 https://it.psychopharmacologyinstitute.com/section/dosaggio-degli-ssri-nel-doc-oltre-le-linee-guida-fda-it/ 2026-09-01T16:41:37+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-del-doc-oltre-i-trattamenti-di-prima-linea-it/ 2026-09-01T16:41:41+00:00 https://it.psychopharmacologyinstitute.com/section/panoramica-delle-strategie-di-aumentazione-nel-doc-it/ 2026-09-01T16:41:45+00:00 https://it.psychopharmacologyinstitute.com/section/potenziamento-glutamatergico-nel-doc-memantina-riluzolo-lamotrigina-e-altri-agenti-it/ 2026-09-01T16:41:49+00:00 https://it.psychopharmacologyinstitute.com/section/antipsicotici-di-seconda-generazione-per-l-augmentazione-nel-doc-agenti-di-terza-linea-it/ 2026-09-01T16:41:53+00:00 https://it.psychopharmacologyinstitute.com/section/altri-potenziatori-nel-doc-buspirona-ondansetron-e-opzioni-emergenti-it/ 2026-09-01T16:41:57+00:00 https://it.psychopharmacologyinstitute.com/section/neurostimolazione-per-il-doc-tms-e-dbs-it/ 2026-09-01T16:42:01+00:00 https://it.psychopharmacologyinstitute.com/section/chirurgia-ablativa-per-il-doc-it/ 2026-09-01T16:42:06+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-ottimizzazione-degli-ssri-prima-dell-augmentazione-it/ 2026-09-01T16:42:10+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-it/ 2026-09-01T16:42:14+00:00 https://it.psychopharmacologyinstitute.com/section/tendenze-attuali-nell-uso-degli-antidepressivi-e-linee-guida-sulla-sospensione-it/ 2026-09-01T16:42:22+00:00 https://it.psychopharmacologyinstitute.com/section/meccanismi-neurobiologici-dell-astinenza-da-antidepressivi-it/ 2026-09-01T16:42:26+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosi-della-sindrome-da-sospensione-degli-antidepressivi-distinzione-dalla-ricaduta-it/ 2026-09-01T16:42:30+00:00 https://it.psychopharmacologyinstitute.com/section/deprescrizione-degli-antidepressivi-razionale-clinico-e-principali-ostacoli-it/ 2026-09-01T16:42:34+00:00 https://it.psychopharmacologyinstitute.com/section/riduzione-iperbolica-degli-antidepressivi-basi-neurobiologiche-it/ 2026-09-01T16:42:37+00:00 https://it.psychopharmacologyinstitute.com/section/sospensione-iperbolica-degli-antidepressivi-evidenze-cliniche-it/ 2026-09-01T16:42:42+00:00 https://it.psychopharmacologyinstitute.com/section/implementazione-della-riduzione-iperbolica-degli-antidepressivi-opzioni-farmaceutiche-e-considerazioni-cliniche-it/ 2026-09-01T16:42:45+00:00 https://it.psychopharmacologyinstitute.com/section/deprescrizione-di-ssri-e-mirtazapina-tecniche-di-riduzione-iperbolica-it/ 2026-09-01T16:42:49+00:00 https://it.psychopharmacologyinstitute.com/section/deprescrizione-degli-snri-tecniche-di-riduzione-iperbolica-del-dosaggio-it/ 2026-09-01T16:42:53+00:00 https://it.psychopharmacologyinstitute.com/section/casi-clinici-it/ 2026-09-01T16:42:57+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9811-it/ 2026-09-01T16:43:00+00:00 https://it.psychopharmacologyinstitute.com/section/unintroduzione-alluso-di-farmaci-naturali-per-i-disturbi-psichiatrici-2/ 2026-09-01T16:43:07+00:00 https://it.psychopharmacologyinstitute.com/section/esplorare-levidenza-della-n-acetilcisteina-nac-per-i-disturbi-dellumore/ 2026-09-01T16:43:11+00:00 https://it.psychopharmacologyinstitute.com/section/prove-di-nac-in-altri-disturbi-psichiatrici-2/ 2026-09-01T16:43:15+00:00 https://it.psychopharmacologyinstitute.com/section/inositolo-indicazioni-potenziali-somministrazione-e-una-vignetta-clinica-2/ 2026-09-01T16:43:19+00:00 https://it.psychopharmacologyinstitute.com/section/cannabidiolo-evidenze-per-i-disturbi-psichiatrici-e-raccomandazioni-per-il-suo-utilizzo/ 2026-09-01T16:43:24+00:00 https://it.psychopharmacologyinstitute.com/section/uso-di-acido-folico-e-l-metilfolato-nei-disturbi-psichiatrici/ 2026-09-01T16:43:27+00:00 https://it.psychopharmacologyinstitute.com/section/ashwagandha-asw-potenziali-indicazioni-e-somministrazione-nei-disturbi-psichiatrici-2/ 2026-09-01T16:43:31+00:00 https://it.psychopharmacologyinstitute.com/section/potenziali-combinazioni-di-farmaci-naturali-per-i-disturbi-psichiatrici/ 2026-09-01T16:43:34+00:00 https://it.psychopharmacologyinstitute.com/section/raccomandazioni-per-luso-di-farmaci-naturali-nei-disturbi-psichiatrici-2/ 2026-09-01T16:43:38+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-8/ 2026-09-01T16:43:42+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-dei-disturbi-del-comportamento-alimentare-panoramica-e-caso-clinico-it/ 2026-09-01T16:43:49+00:00 https://it.psychopharmacologyinstitute.com/section/bulimia-nervosa-farmaci-efficaci-it/ 2026-09-01T16:43:53+00:00 https://it.psychopharmacologyinstitute.com/section/considerazioni-chiave-nella-prescrizione-per-la-bulimia-nervosa-it/ 2026-09-01T16:43:57+00:00 https://it.psychopharmacologyinstitute.com/section/il-ruolo-della-farmacoterapia-nell-anoressia-nervosa-it/ 2026-09-01T16:44:01+00:00 https://it.psychopharmacologyinstitute.com/section/anoressia-con-sintomi-dell-umore-un-approccio-farmacologico-mirato-it/ 2026-09-01T16:44:04+00:00 https://it.psychopharmacologyinstitute.com/section/farmacoterapia-del-disturbo-da-alimentazione-incontrollata-antidepressivi-e-anticonvulsivanti-it/ 2026-09-01T16:44:08+00:00 https://it.psychopharmacologyinstitute.com/section/farmacoterapia-del-disturbo-da-alimentazione-incontrollata-lisdexamfetamina-it/ 2026-09-01T16:44:12+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-decisioni-terapeutiche-nella-bulimia-nervosa-it/ 2026-09-01T16:44:16+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-8109-it/ 2026-09-01T16:44:20+00:00 https://it.psychopharmacologyinstitute.com/section/farmacoterapia-per-il-disturbo-da-uso-di-alcol-evidenze-efficacia-e-lacune-terapeutiche-it/ 2026-09-01T16:44:28+00:00 https://it.psychopharmacologyinstitute.com/section/naltrexone-nel-disturbo-da-uso-di-alcol-dosaggio-monitoraggio-e-sicurezza-epatica-it/ 2026-09-01T16:44:32+00:00 https://it.psychopharmacologyinstitute.com/section/acamprosato-nel-disturbo-da-uso-di-alcol-meccanismo-d-azione-posologia-efficacia-e-sicurezza-it/ 2026-09-01T16:44:36+00:00 https://it.psychopharmacologyinstitute.com/section/disulfiram-nel-disturbo-da-uso-di-alcol-meccanismi-d-azione-efficacia-e-considerazioni-sulla-sicurezza-epatica-it/ 2026-09-01T16:44:39+00:00 https://it.psychopharmacologyinstitute.com/section/gabapentin-topiramato-e-baclofen-nel-disturbo-da-uso-di-alcol-it/ 2026-09-01T16:44:43+00:00 https://it.psychopharmacologyinstitute.com/section/algoritmo-per-il-disturbo-da-uso-di-alcol-selezione-della-farmacoterapia-in-base-allo-stato-epatico-it/ 2026-09-01T16:44:47+00:00 https://it.psychopharmacologyinstitute.com/section/disturbo-da-uso-di-alcol-con-comorbilita-respiratorie-e-infettive-aggiustamenti-farmacologici-it/ 2026-09-01T16:44:52+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-del-disturbo-da-uso-di-alcol-in-pazienti-con-comorbilita-cardiovascolare-e-renale-it/ 2026-09-01T16:44:58+00:00 https://it.psychopharmacologyinstitute.com/section/vignetta-clinica-it/ 2026-09-01T16:45:02+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9210-it/ 2026-09-01T16:45:06+00:00 https://it.psychopharmacologyinstitute.com/section/definire-l-insonnia-diagnosi-e-fisiopatologia-it/ 2026-09-01T16:45:14+00:00 https://it.psychopharmacologyinstitute.com/section/epidemiologia-e-screening-dell-insonnia-it/ 2026-09-01T16:45:18+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-di-prima-linea-per-l-insonnia-focus-sulla-cbt-i-it/ 2026-09-01T16:45:22+00:00 https://it.psychopharmacologyinstitute.com/section/antagonisti-duali-dei-recettori-dell-oressina-efficacia-dosaggio-e-sicurezza-it/ 2026-09-01T16:45:26+00:00 https://it.psychopharmacologyinstitute.com/section/z-drug-e-benzodiazepine-per-l-insonnia-it/ 2026-09-01T16:45:30+00:00 https://it.psychopharmacologyinstitute.com/section/agonisti-melatoninergici-dosaggio-qualita-ed-efficacia-di-melatonina-e-ramelteon-it/ 2026-09-01T16:45:34+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-per-l-insonnia-doxepina-trazodone-e-mirtazapina-it/ 2026-09-01T16:45:38+00:00 https://it.psychopharmacologyinstitute.com/section/antipsicotici-antistaminici-e-magnesio-per-l-insonnia-it/ 2026-09-01T16:45:42+00:00 https://it.psychopharmacologyinstitute.com/section/insonnia-in-gravidanza-e-negli-anziani-scegliere-l-agente-piu-sicuro-it/ 2026-09-01T16:45:46+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-eszopiclone-per-l-insonnia-perimenopausale-it/ 2026-09-01T16:45:49+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-10811-it/ 2026-09-01T16:45:53+00:00 https://it.psychopharmacologyinstitute.com/section/sottotipi-del-disturbo-bipolare-presentazioni-classiche-vs-atipiche-it/ 2026-09-01T16:46:01+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-della-depressione-bipolare-esami-di-laboratorio-diari-dell-umore-e-scale-del-temperamento-it/ 2026-09-01T16:46:06+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-bipolare-mista-caratteristiche-cliniche-e-strategie-terapeutiche-it/ 2026-09-01T16:46:10+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-bipolare-sottotipo-infiammatorio-it/ 2026-09-01T16:46:14+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-bipolare-tipo-vascolare-it/ 2026-09-01T16:46:18+00:00 https://it.psychopharmacologyinstitute.com/section/litio-per-la-depressione-bipolare-it/ 2026-09-01T16:46:22+00:00 https://it.psychopharmacologyinstitute.com/section/lamotrigina-per-la-depressione-bipolare-it/ 2026-09-01T16:46:26+00:00 https://it.psychopharmacologyinstitute.com/section/antipsicotici-di-seconda-generazione-per-la-depressione-bipolare-it/ 2026-09-01T16:46:29+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-aggiuntivi-per-la-depressione-bipolare-pramipexolo-t3-e-fototerapia-it/ 2026-09-01T16:46:33+00:00 https://it.psychopharmacologyinstitute.com/section/modafinil-omega-3-e-altre-opzioni-di-terza-linea-per-la-depressione-bipolare-it/ 2026-09-01T16:46:37+00:00 https://it.psychopharmacologyinstitute.com/section/ketamina-tms-ed-ect-per-la-depressione-bipolare-it/ 2026-09-01T16:46:42+00:00 https://it.psychopharmacologyinstitute.com/section/punti-chiave-it/ 2026-09-01T16:46:46+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-collaterali-degli-antipsicotici-panoramica-dei-profili-recettoriali-it/ 2026-09-01T16:46:53+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-della-sedazione-indotta-dagli-antipsicotici-it/ 2026-09-01T16:46:57+00:00 https://it.psychopharmacologyinstitute.com/section/aumento-di-peso-indotto-dagli-antipsicotici-prevenzione-e-gestione-it/ 2026-09-01T16:47:01+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-terapeutiche-per-acatisia-e-parkinsonismo-it/ 2026-09-01T16:47:05+00:00 https://it.psychopharmacologyinstitute.com/section/riconoscimento-e-gestione-della-sindrome-neurolettica-maligna-e-della-distonia-acuta-it/ 2026-09-01T16:47:09+00:00 https://it.psychopharmacologyinstitute.com/section/discinesia-tardiva-indotta-da-antipsicotici-valutazione-e-monitoraggio-it/ 2026-09-01T16:47:13+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-della-discinesia-tardiva-indotta-da-antipsicotici-it/ 2026-09-01T16:47:17+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-dell-iperprolattinemia-e-degli-effetti-collaterali-sessuali-da-uso-di-antipsicotici-it/ 2026-09-01T16:47:21+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-degli-effetti-collaterali-cardiaci-del-trattamento-antipsicotico-it/ 2026-09-01T16:47:25+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-dell-ipotensione-ortostatica-e-delle-convulsioni-indotte-dagli-antipsicotici-it/ 2026-09-01T16:47:28+00:00 https://it.psychopharmacologyinstitute.com/section/problemi-gastrointestinali-indotti-dagli-antipsicotici-scialorrea-e-stipsi-it/ 2026-09-01T16:47:32+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9312-it/ 2026-09-01T16:47:36+00:00 https://it.psychopharmacologyinstitute.com/section/imparare-le-basi-del-sonno/ 2026-09-01T16:47:44+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-la-relazione-tra-disturbo-da-insonnia-e-ddm-2/ 2026-09-01T16:47:48+00:00 https://it.psychopharmacologyinstitute.com/section/approcci-diagnostici-e-strategie-di-valutazione-dellinsonnia/ 2026-09-01T16:47:52+00:00 https://it.psychopharmacologyinstitute.com/section/interventi-non-farmacologici-per-linsonnia/ 2026-09-01T16:47:56+00:00 https://it.psychopharmacologyinstitute.com/section/interventi-farmacologici-per-linsonnia-benzodiazepine-e-ipnotici-non-benzodiazepinici/ 2026-09-01T16:48:00+00:00 https://it.psychopharmacologyinstitute.com/section/altri-interventi-farmacologici-per-linsonnia/ 2026-09-01T16:48:04+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-di-trattamento-per-la-gestione-dellinsonnia-nel-ddm/ 2026-09-01T16:48:08+00:00 https://it.psychopharmacologyinstitute.com/section/ruolo-dei-trattamenti-con-ketamina-e-neurostimolazione-nellinsonnia-in-comorbilita-con-ddm-2/ 2026-09-01T16:48:12+00:00 https://it.psychopharmacologyinstitute.com/section/vignetta-clinica-il-signor-b-2/ 2026-09-01T16:48:17+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-7/ 2026-09-01T16:48:21+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-la-catatonia-terminologia-e-sottotipi-it/ 2026-09-01T16:48:30+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosi-di-catatonia-suggerimenti-per-la-valutazione-it/ 2026-09-01T16:48:35+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosi-della-catatonia-il-test-di-provocazione-con-lorazepam-it/ 2026-09-01T16:48:40+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosi-differenziale-e-identificazione-delle-cause-sottostanti-della-catatonia-it/ 2026-09-01T16:48:44+00:00 https://it.psychopharmacologyinstitute.com/section/complicazioni-mediche-e-considerazioni-prognostiche-nella-catatonia-it/ 2026-09-01T16:48:48+00:00 https://it.psychopharmacologyinstitute.com/section/farmacoterapia-della-catatonia-il-ruolo-delle-benzodiazepine-it/ 2026-09-01T16:48:53+00:00 https://it.psychopharmacologyinstitute.com/section/terapie-di-neuromodulazione-ect-e-rtms-nella-catatonia-it/ 2026-09-01T16:48:58+00:00 https://it.psychopharmacologyinstitute.com/section/antagonisti-nmda-nel-trattamento-della-catatonia-amantadina-memantina-e-ketamina-it/ 2026-09-01T16:49:02+00:00 https://it.psychopharmacologyinstitute.com/section/altre-strategie-farmacologiche-per-la-catatonia-zolpidem-bromocriptina-e-cariprazina-it/ 2026-09-01T16:49:06+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-9410-it/ 2026-09-01T16:49:10+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9411-it/ 2026-09-01T16:49:15+00:00 https://it.psychopharmacologyinstitute.com/section/funzionamento-sessuale-prospettive-biopsicosociali-e-neurobiologiche-it/ 2026-09-01T16:49:24+00:00 https://it.psychopharmacologyinstitute.com/section/disfunzione-sessuale-come-sintomo-effetto-collaterale-e-fattore-di-rischio-per-la-depressione-it/ 2026-09-01T16:49:28+00:00 https://it.psychopharmacologyinstitute.com/section/condizioni-mediche-e-farmaci-non-psichiatrici-che-influenzano-la-funzione-sessuale-it/ 2026-09-01T16:49:32+00:00 https://it.psychopharmacologyinstitute.com/section/disfunzione-sessuale-indotta-dagli-antidepressivi-meccanismi-genetica-e-prevalenza-it/ 2026-09-01T16:49:36+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-con-basso-rischio-di-disfunzione-sessuale-evidenze-dagli-studi-clinici-it/ 2026-09-01T16:49:40+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-collaterali-sessuali-degli-antipsicotici-degli-stabilizzatori-dell-umore-e-delle-benzodiazepine-it/ 2026-09-01T16:49:44+00:00 https://it.psychopharmacologyinstitute.com/section/comunicare-sulla-funzione-sessuale-un-imperativo-clinico-it/ 2026-09-01T16:49:48+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-della-disfunzione-sessuale-indotta-da-sri-sostituzione-antidoti-e-fattori-modificabili-it/ 2026-09-01T16:49:52+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-contraccettivi-orali-come-causa-trascurata-di-disfunzione-sessuale-it/ 2026-09-01T16:49:56+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9910-it/ 2026-09-01T16:50:00+00:00 https://it.psychopharmacologyinstitute.com/section/una-panoramica-sulluso-di-sostanze-e-sullabuso-di-oppioidi-2/ 2026-09-01T16:50:08+00:00 https://it.psychopharmacologyinstitute.com/section/capire-lintossicazione-e-lastinenza-da-oppioidi/ 2026-09-01T16:50:12+00:00 https://it.psychopharmacologyinstitute.com/section/una-guida-completa-al-trattamento-delloud-2/ 2026-09-01T16:50:17+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-personalizzata-del-paziente-una-chiave-per-un-trattamento-efficace-delloud-2/ 2026-09-01T16:50:21+00:00 https://it.psychopharmacologyinstitute.com/section/metadone-per-la-gestione-delloud/ 2026-09-01T16:50:25+00:00 https://it.psychopharmacologyinstitute.com/section/buprenorfina-per-la-gestione-delloud-2/ 2026-09-01T16:50:29+00:00 https://it.psychopharmacologyinstitute.com/section/esame-dellefficacia-del-naltrexone-a-rilascio-prolungato-oud/ 2026-09-01T16:50:33+00:00 https://it.psychopharmacologyinstitute.com/section/il-ruolo-del-naloxone-nella-gestione-delloud/ 2026-09-01T16:50:37+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-inizio-del-trattamento-con-buprenorfina/ 2026-09-01T16:50:41+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-12/ 2026-09-01T16:50:45+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-i-geni-farmacocinetici-e-farmacodinamici-2/ 2026-09-01T16:50:53+00:00 https://it.psychopharmacologyinstitute.com/section/in-che-modo-i-geni-farmacocinetici-influenzano-il-metabolismo-dei-farmaci/ 2026-09-01T16:50:57+00:00 https://it.psychopharmacologyinstitute.com/section/test-farmacogenetici-importanti-nella-pratica-psichiatrica/ 2026-09-01T16:51:01+00:00 https://it.psychopharmacologyinstitute.com/section/dosaggio-guidato-dalla-farmacogenetica-strategie-per-i-metabolizzatori-scarsi-e-rapidi-2/ 2026-09-01T16:51:04+00:00 https://it.psychopharmacologyinstitute.com/section/i-pannelli-farmacogenetici-funzionano-davvero-2/ 2026-09-01T16:51:08+00:00 https://it.psychopharmacologyinstitute.com/section/gene-sert-e-risposta-agli-ssri-e-clinicamente-utile/ 2026-09-01T16:51:13+00:00 https://it.psychopharmacologyinstitute.com/section/il-gene-mthfr-lanello-debole-nel-trattamento-della-depressione-da-l-metilfolato/ 2026-09-01T16:51:17+00:00 https://it.psychopharmacologyinstitute.com/section/i-test-genetici-possono-causare-piu-danni-che-benefici-2/ 2026-09-01T16:51:21+00:00 https://it.psychopharmacologyinstitute.com/section/caso-gestione-del-dosaggio-di-citalopram-nei-metabolizzatori-poveri-di-cyp2c19/ 2026-09-01T16:51:24+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-14/ 2026-09-01T16:51:28+00:00 https://it.psychopharmacologyinstitute.com/section/panoramica-del-disturbo-dello-spettro-autistico/ 2026-09-01T16:51:36+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-delliperattivita-motoria-e-della-disattenzione-nei-dsa-stimolanti/ 2026-09-01T16:51:41+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-delliperattivita-motoria-e-della-disattenzione-nei-dsa-non-stimolanti/ 2026-09-01T16:51:45+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-dei-comportamenti-ripetitivi-nei-dsa-antidepressivi/ 2026-09-01T16:51:49+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-della-depressione-e-dellansia-nei-dsa-antidepressivi-e-altre-strategie/ 2026-09-01T16:51:53+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-dellirritabilita-nei-dsa-risperidone-e-aripiprazolo/ 2026-09-01T16:51:57+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-dellirritabilita-nei-dsa-altri-farmaci-antipsicotici-e-parent-training/ 2026-09-01T16:52:01+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-dellirritabilita-nei-dsa-stabilizzatori-dellumore-e-altre-strategie/ 2026-09-01T16:52:04+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-dei-disturbi-del-sonno-nel-dsa-melatonina-e-altre-strategie/ 2026-09-01T16:52:08+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-della-compromissione-della-relazione-sociale-nel-dsa/ 2026-09-01T16:52:11+00:00 https://it.psychopharmacologyinstitute.com/section/la-psicofarmacologia-dellagitazione-gestione-delle-emergenze-comportamentali/ 2026-09-01T16:52:22+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-dellagitazione-valutazione-medica-scale-di-valutazione-e-diagnosi-differenziale-2/ 2026-09-01T16:52:26+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosi-psichiatriche-in-pazienti-agitati-delirium-demenza-e-disturbi-psicotici-2/ 2026-09-01T16:52:31+00:00 https://it.psychopharmacologyinstitute.com/section/altre-diagnosi-psichiatriche-in-pazienti-agitati-disturbi-dellumore-e-da-uso-di-sostanze/ 2026-09-01T16:52:35+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-non-farmacologiche-per-la-gestione-dellagitazione-la-de-escalation-verbale-2/ 2026-09-01T16:52:39+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-farmacologiche-per-la-gestione-dellagitazione-raccomandazioni-generali-e-obiettivi-di-trattamento/ 2026-09-01T16:52:43+00:00 https://it.psychopharmacologyinstitute.com/section/il-ruolo-degli-antipsicotici-nella-gestione-dellagitazione/ 2026-09-01T16:52:47+00:00 https://it.psychopharmacologyinstitute.com/section/il-ruolo-delle-benzodiazepine-e-della-dexmedetomidina-nella-gestione-dellagitazione-2/ 2026-09-01T16:52:51+00:00 https://it.psychopharmacologyinstitute.com/section/vignetta-clinica-un-approccio-alternativo-ai-pazienti-agitati/ 2026-09-01T16:52:55+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-2-5/ 2026-09-01T16:52:59+00:00 https://it.psychopharmacologyinstitute.com/section/esplorazione-delle-indicazioni-e-degli-usi-off-label-della-lamotrigina/ 2026-09-01T16:53:06+00:00 https://it.psychopharmacologyinstitute.com/section/comprensione-dei-meccanismi-della-lamotrigina-e-dello-schema-di-titolazione-2/ 2026-09-01T16:53:10+00:00 https://it.psychopharmacologyinstitute.com/section/lamotrigina-effetti-collaterali-e-considerazioni-speciali/ 2026-09-01T16:53:14+00:00 https://it.psychopharmacologyinstitute.com/section/esplorazione-dei-potenziali-effetti-collaterali-cardiaci-di-lamotrigina-e-ms-un-caso/ 2026-09-01T16:53:18+00:00 https://it.psychopharmacologyinstitute.com/section/effetto-della-lamotrigina-sul-prolungamento-del-qtc-e-sullampliamento-del-qrs-2/ 2026-09-01T16:53:22+00:00 https://it.psychopharmacologyinstitute.com/section/altre-complicazioni-cardiache-associate-alluso-di-lamotrigina/ 2026-09-01T16:53:26+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-per-luso-sicuro-e-il-corretto-monitoraggio-della-lamotrigina-2/ 2026-09-01T16:53:29+00:00 https://it.psychopharmacologyinstitute.com/section/un-approccio-pratico-nel-caso-di-ms-il-caso-di-a-2/ 2026-09-01T16:53:33+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-10/ 2026-09-01T16:53:37+00:00 https://it.psychopharmacologyinstitute.com/section/introduzione-e-come-convincere-i-pazienti-ad-assumere-il-litio-it/ 2026-09-01T16:53:45+00:00 https://it.psychopharmacologyinstitute.com/section/test-di-base-monitoraggio-e-dosaggio-ottimale-del-litio-it/ 2026-09-01T16:53:49+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-degli-effetti-collaterali-renali-della-terapia-con-litio-it/ 2026-09-01T16:53:53+00:00 https://it.psychopharmacologyinstitute.com/section/come-mitigare-l-aumento-di-peso-e-gli-effetti-collaterali-gastrointestinali-del-litio-it/ 2026-09-01T16:53:56+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-della-disfunzione-tiroidea-e-paratiroidea-in-corso-di-terapia-con-litio-it/ 2026-09-01T16:54:00+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-del-deterioramento-cognitivo-e-del-tremore-indotti-dal-litio-it/ 2026-09-01T16:54:04+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-della-disfunzione-sessuale-dell-alopecia-e-degli-esantemi-da-litio-it/ 2026-09-01T16:54:08+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-il-litio-nella-gestione-di-un-paziente-complesso-con-disturbo-bipolare-it/ 2026-09-01T16:54:12+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-8709-it/ 2026-09-01T16:54:16+00:00 https://it.psychopharmacologyinstitute.com/section/unintroduzione-alluso-della-bsm-nella-pratica-clinica/ 2026-09-01T16:54:23+00:00 https://it.psychopharmacologyinstitute.com/section/bsms-ingredienti-e-dosi/ 2026-09-01T16:54:27+00:00 https://it.psychopharmacologyinstitute.com/section/bsms-sicurezza-e-tollerabilita/ 2026-09-01T16:54:30+00:00 https://it.psychopharmacologyinstitute.com/section/bsms-e-potenziamento-dei-farmaci-psicotropi/ 2026-09-01T16:54:34+00:00 https://it.psychopharmacologyinstitute.com/section/controindicazioni-rigorose-e-relative-alluso-di-bsms/ 2026-09-01T16:54:37+00:00 https://it.psychopharmacologyinstitute.com/section/bsms-e-interazioni-tra-farmaci/ 2026-09-01T16:54:41+00:00 https://it.psychopharmacologyinstitute.com/section/consigli-pratici-per-lutilizzo-dei-sistemi-di-gestione-del-rischio-nella-pratica-clinica/ 2026-09-01T16:54:45+00:00 https://it.psychopharmacologyinstitute.com/section/dosaggio-empowerplus-avanzato-e-nutrienti-essenziali-giornalieri/ 2026-09-01T16:54:49+00:00 https://it.psychopharmacologyinstitute.com/section/avviare-i-bsm-nella-pratica-clinica-un-processo-graduale/ 2026-09-01T16:54:53+00:00 https://it.psychopharmacologyinstitute.com/section/altre-considerazioni-sullutilizzo-di-bsms/ 2026-09-01T16:54:57+00:00 https://it.psychopharmacologyinstitute.com/section/casi-clinici/ 2026-09-01T16:55:00+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-5/ 2026-09-01T16:55:04+00:00 https://it.psychopharmacologyinstitute.com/section/un-background-sulle-parasonnie/ 2026-09-01T16:55:11+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosi-del-disturbo-alimentare-legato-al-sonno-sred/ 2026-09-01T16:55:15+00:00 https://it.psychopharmacologyinstitute.com/section/sred-sonnambulismo-e-guida-in-stato-di-ebbrezza-indotti-da-farmaci/ 2026-09-01T16:55:19+00:00 https://it.psychopharmacologyinstitute.com/section/zolpidem-e-comportamenti-amnestici-complessi-durante-il-sonno/ 2026-09-01T16:55:22+00:00 https://it.psychopharmacologyinstitute.com/section/sonnambulismo-e-sred-indotti-da-zolpidem/ 2026-09-01T16:55:26+00:00 https://it.psychopharmacologyinstitute.com/section/predittori-di-rischio-per-i-comportamenti-complessi-del-sonno-legati-allipnosi/ 2026-09-01T16:55:30+00:00 https://it.psychopharmacologyinstitute.com/section/parasonnie-tra-i-pazienti-psichiatrici-ambulatoriali-risultati-della-sred/ 2026-09-01T16:55:33+00:00 https://it.psychopharmacologyinstitute.com/section/casi-clinici-e-video/ 2026-09-01T16:55:37+00:00 https://it.psychopharmacologyinstitute.com/section/farmaci-per-l-adhd-ed-effetti-collaterali-cardiaci-cosa-mostra-realmente-l-evidenza-it/ 2026-09-01T16:55:49+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-e-anticoagulanti-gestione-del-rischio-emorragico-it/ 2026-09-01T16:55:53+00:00 https://it.psychopharmacologyinstitute.com/section/scelta-degli-antipsicotici-nei-pazienti-in-terapia-anticoagulante-interazioni-farmacologiche-e-alternative-piu-sicure-it/ 2026-09-01T16:55:57+00:00 https://it.psychopharmacologyinstitute.com/section/stabilizzatori-dell-umore-e-anticoagulazione-valproato-carbamazepina-litio-e-lamotrigina-it/ 2026-09-01T16:56:01+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-in-emodialisi-sicurezza-cardiaca-e-aggiustamenti-posologici-it/ 2026-09-01T16:56:07+00:00 https://it.psychopharmacologyinstitute.com/section/antipsicotici-in-emodialisi-strategie-depot-rischio-qt-e-dosaggio-farmaco-specifico-it/ 2026-09-01T16:56:11+00:00 https://it.psychopharmacologyinstitute.com/section/stabilizzatori-dell-umore-in-emodialisi-dosaggio-di-litio-valproato-e-lamotrigina-it/ 2026-09-01T16:56:15+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-quando-il-paziente-non-puo-deglutire-vie-di-somministrazione-farmaci-disponibili-e-indicazioni-pratiche-it/ 2026-09-01T16:56:19+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-disturbo-schizoaffettivo-infarto-miocardico-e-insufficienza-renale-acuta-it/ 2026-09-01T16:56:23+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-10410-it/ 2026-09-01T16:56:27+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-perinatale-superare-le-barriere-e-aumentare-la-fiducia-clinica-it/ 2026-09-01T16:56:34+00:00 https://it.psychopharmacologyinstitute.com/section/impatto-della-gravidanza-sull-efficacia-dei-farmaci-e-considerazioni-sul-dosaggio-it/ 2026-09-01T16:56:39+00:00 https://it.psychopharmacologyinstitute.com/section/farmaci-psichiatrici-in-gravidanza-bilanciare-il-benessere-materno-e-fetale-it/ 2026-09-01T16:56:43+00:00 https://it.psychopharmacologyinstitute.com/section/litio-in-gravidanza-e-allattamento-it/ 2026-09-01T16:56:47+00:00 https://it.psychopharmacologyinstitute.com/section/trattamento-con-ssri-in-gravidanza-un-caso-clinico-it/ 2026-09-01T16:56:50+00:00 https://it.psychopharmacologyinstitute.com/section/valproato-in-gravidanza-considerazioni-fondamentali-it/ 2026-09-01T16:56:54+00:00 https://it.psychopharmacologyinstitute.com/section/gravidanza-adhd-e-stimolanti-prendere-una-decisione-consapevole-1-gestione-dell-adhd-in-gravidanza-bilanciare-rischi-e-benefici-2-sicurezza-degli-stimolanti-in-gravidanza-indicazioni-per-una-scelta-in/ 2026-09-01T16:56:58+00:00 https://it.psychopharmacologyinstitute.com/section/risorse-di-psichiatria-perinatale-ampliare-la-propria-competenza-it/ 2026-09-01T16:57:02+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-8909-it/ 2026-09-01T16:57:05+00:00 https://it.psychopharmacologyinstitute.com/section/malattia-fisica-e-disturbi-da-uso-di-sostanze-una-relazione-bidirezionale-it/ 2026-09-01T16:57:13+00:00 https://it.psychopharmacologyinstitute.com/section/complicanze-epatiche-nei-disturbi-da-uso-di-sostanze-fattori-di-rischio-e-progressione-della-malattia-it/ 2026-09-01T16:57:17+00:00 https://it.psychopharmacologyinstitute.com/section/epatopatia-e-disturbo-da-uso-di-alcol-priorita-tra-disulfiram-naltrexone-e-acamprosato-it/ 2026-09-01T16:57:21+00:00 https://it.psychopharmacologyinstitute.com/section/epatopatia-buprenorfina-metadone-e-farmaci-per-la-cessazione-del-fumo-it/ 2026-09-01T16:57:25+00:00 https://it.psychopharmacologyinstitute.com/section/hiv-epatite-c-e-dipendenza-adeguamento-di-buprenorfina-metadone-naltrexone-e-disulfiram-con-gli-antivirali-it/ 2026-09-01T16:57:29+00:00 https://it.psychopharmacologyinstitute.com/section/insufficienza-renale-e-farmacoterapia-delle-dipendenze-adeguamento-di-naltrexone-acamprosato-gabapentin-e-topiramato-it/ 2026-09-01T16:57:32+00:00 https://it.psychopharmacologyinstitute.com/section/bpco-apnea-del-sonno-e-farmacoterapia-delle-dipendenze-metadone-buprenorfina-gabapentin-e-baclofen-it/ 2026-09-01T16:57:36+00:00 https://it.psychopharmacologyinstitute.com/section/malattie-cardiovascolari-e-farmacoterapia-delle-dipendenze-rischio-qtc-cessazione-del-fumo-e-sicurezza-del-disulfiram-it/ 2026-09-01T16:57:40+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-disturbo-da-uso-di-alcol-con-transaminasi-elevate-it/ 2026-09-01T16:57:44+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-10210-it/ 2026-09-01T16:57:48+00:00 https://it.psychopharmacologyinstitute.com/section/la-scienza-dellarte-della-psicofarmacoterapia/ 2026-09-01T16:57:55+00:00 https://it.psychopharmacologyinstitute.com/section/la-teoria-biologica-della-malattia-e-lo-stigma/ 2026-09-01T16:57:59+00:00 https://it.psychopharmacologyinstitute.com/section/alleanza-farmacoterapeutica-preferenze-terapeutiche-e-comunicazione-2/ 2026-09-01T16:58:02+00:00 https://it.psychopharmacologyinstitute.com/section/abilita-psicoterapeutiche-nella-pratica-quotidiana-psicoterapia-medica-ordinaria-2/ 2026-09-01T16:58:07+00:00 https://it.psychopharmacologyinstitute.com/section/il-caso-di-m-parte-1-2/ 2026-09-01T16:58:11+00:00 https://it.psychopharmacologyinstitute.com/section/il-caso-di-m-parte-2/ 2026-09-01T16:58:15+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-9/ 2026-09-01T16:58:19+00:00 https://it.psychopharmacologyinstitute.com/section/la-prescrizione-nellera-della-psichiatria-biomedica-unintroduzione/ 2026-09-01T16:58:26+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-il-problema-della-resistenza-al-trattamento-2/ 2026-09-01T16:58:30+00:00 https://it.psychopharmacologyinstitute.com/section/assumere-una-prospettiva-integrativa-2/ 2026-09-01T16:58:34+00:00 https://it.psychopharmacologyinstitute.com/section/concetti-psicodinamici-di-base-2/ 2026-09-01T16:58:38+00:00 https://it.psychopharmacologyinstitute.com/section/introduzione-alla-psicofarmacologia-psicodinamica-2/ 2026-09-01T16:58:42+00:00 https://it.psychopharmacologyinstitute.com/section/evitare-la-scissione-mente-corpo-le-fonti-del-pensiero-dualistico/ 2026-09-01T16:58:45+00:00 https://it.psychopharmacologyinstitute.com/section/integrazione-mente-corpo-nellassistenza-psichiatrica/ 2026-09-01T16:58:49+00:00 https://it.psychopharmacologyinstitute.com/section/conoscere-il-paziente-2/ 2026-09-01T16:58:53+00:00 https://it.psychopharmacologyinstitute.com/section/attenzione-allambivalenza-del-paziente/ 2026-09-01T16:58:57+00:00 https://it.psychopharmacologyinstitute.com/section/coltivare-unalleanza-terapeutica-2/ 2026-09-01T16:59:00+00:00 https://it.psychopharmacologyinstitute.com/section/affrontare-gli-usi-controterapeutici-dei-farmaci-e-del-controtransfert/ 2026-09-01T16:59:04+00:00 https://it.psychopharmacologyinstitute.com/section/vignette-cliniche-2/ 2026-09-01T16:59:07+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-2-3/ 2026-09-01T16:59:11+00:00 https://it.psychopharmacologyinstitute.com/section/funzione-cognitiva-e-traiettorie-di-risposta-al-trattamento-nella-schizofrenia-al-primo-episodio-evidenze-da-uno-studio-di-coorte-prospettico-it/ 2026-09-01T16:59:18+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-per-il-trattamento-degli-adulti-con-disturbo-depressivo-maggiore-nella-fase-di-mantenimento-una-revisione-sistematica-e-network-meta-analisi-it/ 2026-09-01T16:59:22+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-di-aumentazione-per-la-resistenza-alla-clozapina-una-revisione-sistematica-e-meta-analisi-it/ 2026-09-01T16:59:26+00:00 https://it.psychopharmacologyinstitute.com/section/la-proteina-c-reattiva-potrebbe-predire-l-efficacia-degli-ssri-nella-pratica-clinica-uno-studio-di-coorte-su-grandi-campioni-nel-mondo-reale-it/ 2026-09-01T16:59:29+00:00 https://it.psychopharmacologyinstitute.com/section/effetto-del-farmaco-ansiolitico-silexan-sul-sonno-una-revisione-narrativa-it/ 2026-09-01T16:59:32+00:00 https://it.psychopharmacologyinstitute.com/section/associazioni-tra-uso-di-antipsicotici-uso-di-sostanze-e-rischio-di-ricaduta-nei-pazienti-con-schizofrenia-evidenze-dal-mondo-reale-da-2-coorti-nazionali-it/ 2026-09-01T16:59:39+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-nuovi-ed-emergenti-per-la-depressione-maggiore-it/ 2026-09-01T16:59:43+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-di-un-intervento-di-auto-gestione-basato-su-smartphone-per-individui-con-disturbo-bipolare-su-recidiva-carico-sintomatologico-e-qualita-della-vita-it/ 2026-09-01T16:59:46+00:00 https://it.psychopharmacologyinstitute.com/section/pattern-di-utilizzo-delle-sigarette-elettroniche-aromi-e-caratteristiche-dei-dispositivi-associati-alla-cessazione-del-fumo-in-un-campione-statunitense-di-adulti-che-utilizzano-le-sigarette-elettronic/ 2026-09-01T16:59:50+00:00 https://it.psychopharmacologyinstitute.com/section/effetto-dei-test-farmacogenomici-per-le-interazioni-farmaco-gene-sulla-selezione-dei-farmaci-e-sulla-remissione-dei-sintomi-nel-disturbo-depressivo-maggiore-il-trial-clinico-randomizzato-prime-care-it/ 2026-09-01T16:59:54+00:00 https://it.psychopharmacologyinstitute.com/section/aloperidolo-nel-trattamento-del-delirium-nei-pazienti-in-terapia-intensiva-it/ 2026-09-01T17:00:02+00:00 https://it.psychopharmacologyinstitute.com/section/uso-di-antidepressivi-in-gravidanza-e-rischio-di-diabete-gestazionale-una-revisione-sistematica-e-meta-analisi-it/ 2026-09-01T17:00:05+00:00 https://it.psychopharmacologyinstitute.com/section/rischio-di-malattie-cardiovascolari-associato-ai-farmaci-utilizzati-nel-disturbo-da-deficit-di-attenzione-iperattivita-una-revisione-sistematica-e-meta-analisi-it/ 2026-09-01T17:00:09+00:00 https://it.psychopharmacologyinstitute.com/section/cannabis-connettivita-e-transizione-all-eta-adulta-associazioni-tra-uso-di-cannabis-e-connettivita-della-corteccia-cingolata-anteriore-durante-il-passaggio-all-eta-adulta-it/ 2026-09-01T17:00:12+00:00 https://it.psychopharmacologyinstitute.com/section/uso-di-contraccettivi-ormonali-e-antidepressivi-e-rischio-di-comportamento-suicidario-e-incidenti-nelle-donne-con-disturbi-premestruali-uno-studio-di-coorte-a-livello-nazionale-it/ 2026-09-01T17:00:16+00:00 https://it.psychopharmacologyinstitute.com/section/efficacia-comparativa-sicurezza-e-accettabilita-di-pimavanserin-e-altri-antipsicotici-atipici-per-la-psicosi-nel-morbo-di-parkinson-revisione-sistematica-e-network-meta-analisi-it/ 2026-09-01T17:00:24+00:00 https://it.psychopharmacologyinstitute.com/section/antagonisti-duali-dei-recettori-dell-orexina-per-il-trattamento-dell-insonnia-una-revisione-sistematica-e-meta-analisi-su-trial-randomizzati-in-doppio-cieco-controllati-con-placebo-di-suvorexant-e-lem/ 2026-09-01T17:00:27+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-farmacologici-per-il-craving-da-cocaina-qual-e-la-strada-da-percorrere-una-revisione-sistematica-it/ 2026-09-01T17:00:31+00:00 https://it.psychopharmacologyinstitute.com/section/antipsicotici-di-terza-generazione-in-pazienti-con-schizofrenia-e-non-responsivita-o-intolleranza-al-regime-terapeutico-con-clozapina-quali-sono-le-evidenze-it/ 2026-09-01T17:00:35+00:00 https://it.psychopharmacologyinstitute.com/section/olanzapina-samidorfano-in-giovani-adulti-con-schizofrenia-disturbo-schizofreniforme-o-disturbo-bipolare-i-in-fase-iniziale-di-malattia-risultati-dello-studio-randomizzato-controllato-enlighten-early-i/ 2026-09-01T17:00:39+00:00 https://it.psychopharmacologyinstitute.com/section/la-malattia-di-cade-e-oltre-diagnosi-errata-uso-di-antidepressivi-e-una-definizione-proposta-per-il-disturbo-dello-spettro-bipolare-it/ 2026-09-01T17:00:47+00:00 https://it.psychopharmacologyinstitute.com/section/raccomandazioni-della-canadian-network-for-mood-and-anxiety-treatments-canmat-e-della-international-society-for-bipolar-disorders-isbd-per-la-gestione-dei-pazienti-con-disturbo-bipolare-con-presentazi/ 2026-09-01T17:00:51+00:00 https://it.psychopharmacologyinstitute.com/section/considerazioni-sui-limiti-metodologici-nelle-evidenze-sugli-antidepressivi-per-la-depressione-una-ranalisi-di-una-network-meta-analisi-it/ 2026-09-01T17:00:56+00:00 https://it.psychopharmacologyinstitute.com/section/distinguishing-relapse-from-antidepressant-withdrawal-clinical-practice-and-antidepressant-discontinuation-studies-it/ 2026-09-01T17:01:00+00:00 https://it.psychopharmacologyinstitute.com/section/linee-guida-2018-del-canadian-network-for-mood-and-anxiety-treatments-canmat-e-della-international-society-for-bipolar-disorders-isbd-per-la-gestione-dei-pazienti-con-disturbo-bipolare-it/ 2026-09-01T17:01:04+00:00 https://it.psychopharmacologyinstitute.com/section/effetto-del-brexanolone-sui-sintomi-depressivi-nel-postpartum-sull-ansia-e-sull-insonnia-it/ 2026-09-01T17:01:12+00:00 https://it.psychopharmacologyinstitute.com/section/effetto-della-co-prescrizione-di-aripiprazolo-sui-livelli-di-prolattina-in-pazienti-schizofrenici-con-diabete-mellito-di-tipo-2-it/ 2026-09-01T17:01:16+00:00 https://it.psychopharmacologyinstitute.com/section/sindromi-tardive-manifestazioni-cliniche-e-strategie-terapeutiche-it/ 2026-09-01T17:01:20+00:00 https://it.psychopharmacologyinstitute.com/section/effetto-dei-test-farmacogenomici-sugli-esiti-clinici-nel-disturbo-depressivo-maggiore-it/ 2026-09-01T17:01:24+00:00 https://it.psychopharmacologyinstitute.com/section/l-impatto-del-fattore-stimolante-le-colonie-sugli-esiti-del-re-challenge-con-clozapina-it/ 2026-09-01T17:01:28+00:00 https://it.psychopharmacologyinstitute.com/section/uso-dei-fans-per-la-riduzione-del-rischio-di-delirium-it/ 2026-09-01T17:01:36+00:00 https://it.psychopharmacologyinstitute.com/section/vittimizzazione-in-relazione-alla-violenza-nella-schizofrenia-it/ 2026-09-01T17:01:40+00:00 https://it.psychopharmacologyinstitute.com/section/zuranolone-per-il-trattamento-della-depressione-post-partum-it/ 2026-09-01T17:01:44+00:00 https://it.psychopharmacologyinstitute.com/section/apatia-associata-ai-farmaci-antidepressivi-it/ 2026-09-01T17:01:48+00:00 https://it.psychopharmacologyinstitute.com/section/rischio-di-malformazioni-nei-neonati-dopo-esposizione-alle-benzodiazepine-it/ 2026-09-01T17:01:52+00:00 https://it.psychopharmacologyinstitute.com/section/uso-di-tabacco-dipendenza-da-nicotina-e-cessazione-del-fumo-negli-adulti-con-psicosi-it/ 2026-09-01T17:01:59+00:00 https://it.psychopharmacologyinstitute.com/section/il-trattamento-farmacologico-del-disturbo-ossessivo-compulsivo-it/ 2026-09-01T17:02:03+00:00 https://it.psychopharmacologyinstitute.com/section/rischio-di-disfunzione-sessuale-post-ssri-irreversibile-con-gli-antidepressivi-it/ 2026-09-01T17:02:07+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-preventivi-del-delirium-degli-antagonisti-duali-dei-recettori-dell-orexina-it/ 2026-09-01T17:02:11+00:00 https://it.psychopharmacologyinstitute.com/section/disturbi-del-sonno-nel-morbo-di-parkinson-it/ 2026-09-01T17:02:15+00:00 https://it.psychopharmacologyinstitute.com/section/complicanze-neonatali-e-della-gravidanza-in-seguito-a-depressione-materna-o-esposizione-ad-antidepressivi-it/ 2026-09-01T17:02:23+00:00 https://it.psychopharmacologyinstitute.com/section/interruzione-degli-antidepressivi-in-gravidanza-ed-esiti-psichiatrici-nel-postpartum-it/ 2026-09-01T17:02:27+00:00 https://it.psychopharmacologyinstitute.com/section/potenziamento-con-litio-nel-trattamento-del-disturbo-depressivo-maggiore-it/ 2026-09-01T17:02:30+00:00 https://it.psychopharmacologyinstitute.com/section/sicurezza-degli-antipsicotici-nelle-epatopatie-it/ 2026-09-01T17:02:34+00:00 https://it.psychopharmacologyinstitute.com/section/polifarmacia-e-farmaci-inappropriati-in-associazione-con-antidepressivi-negli-anziani-it/ 2026-09-01T17:02:39+00:00 https://it.psychopharmacologyinstitute.com/section/farmaci-antipsicotici-e-rischio-di-pancreatite-acuta-it/ 2026-09-01T17:02:47+00:00 https://it.psychopharmacologyinstitute.com/section/clozapina-e-il-suo-potenziamento-con-la-ect-nella-schizofrenia-ultra-resistente-al-trattamento-it/ 2026-09-01T17:02:50+00:00 https://it.psychopharmacologyinstitute.com/section/rischio-di-tentativo-di-suicidio-e-suicidio-associati-alle-benzodiazepine-it/ 2026-09-01T17:02:54+00:00 https://it.psychopharmacologyinstitute.com/section/potenziali-benefici-di-silexan-nella-sindrome-post-covid-19-it/ 2026-09-01T17:02:58+00:00 https://it.psychopharmacologyinstitute.com/section/il-trazodone-dovrebbe-essere-la-terapia-di-prima-linea-per-l-insonnia-it/ 2026-09-01T17:03:02+00:00 https://it.psychopharmacologyinstitute.com/section/concentrazioni-plasmatiche-di-ssri-snri-dopo-chirurgia-bariatrica-ed-effetti-sui-sintomi-depressivi-it/ 2026-09-01T17:03:10+00:00 https://it.psychopharmacologyinstitute.com/section/gli-psichedelici-come-terapeutici-trasformativi-it/ 2026-09-01T17:03:15+00:00 https://it.psychopharmacologyinstitute.com/section/uso-degli-antidepressivi-in-pazienti-con-depressione-comorbile-e-malattia-medica-it/ 2026-09-01T17:03:19+00:00 https://it.psychopharmacologyinstitute.com/section/uso-del-daridorexant-per-il-trattamento-dell-insonnia-cronica-it/ 2026-09-01T17:03:23+00:00 https://it.psychopharmacologyinstitute.com/section/un-agenda-di-ricerca-internazionale-per-la-schizofrenia-resistente-alla-clozapina-it/ 2026-09-01T17:03:27+00:00 https://it.psychopharmacologyinstitute.com/section/sintomi-di-insonnia-e-rischio-di-ictus-nell-health-and-retirement-study-it/ 2026-09-01T17:03:35+00:00 https://it.psychopharmacologyinstitute.com/section/efficacia-a-lungo-termine-dei-farmaci-antipsicotici-negli-adulti-con-schizofrenia-it/ 2026-09-01T17:03:39+00:00 https://it.psychopharmacologyinstitute.com/section/sicurezza-comparativa-degli-antipsicotici-orali-per-gli-eventi-avversi-negli-adulti-nel-postoperatorio-it/ 2026-09-01T17:03:43+00:00 https://it.psychopharmacologyinstitute.com/section/cannabis-medica-nel-trattamento-della-malattia-di-parkinson-it/ 2026-09-01T17:03:46+00:00 https://it.psychopharmacologyinstitute.com/section/prevalence-delle-anomalie-neuroradiologiche-nel-primo-episodio-psicotico-it/ 2026-09-01T17:03:51+00:00 https://it.psychopharmacologyinstitute.com/section/cariprazine-come-trattamento-aggiuntivo-nel-disturbo-depressivo-maggiore-it/ 2026-09-01T17:03:59+00:00 https://it.psychopharmacologyinstitute.com/section/efficacia-del-risperidone-a-basso-dosaggio-nel-delirium-post-chirurgico-nei-pazienti-anziani-it/ 2026-09-01T17:04:03+00:00 https://it.psychopharmacologyinstitute.com/section/efficacia-della-memantina-nel-trattamento-della-tricotillomania-e-del-disturbo-da-escoriazione-it/ 2026-09-01T17:04:07+00:00 https://it.psychopharmacologyinstitute.com/section/disturbi-psichiatrici-e-rischio-successivo-di-malattia-cardiovascolare-it/ 2026-09-01T17:04:11+00:00 https://it.psychopharmacologyinstitute.com/section/efficacia-nel-mondo-reale-dei-trattamenti-farmacologici-per-il-disturbo-bipolare-it/ 2026-09-01T17:04:15+00:00 https://it.psychopharmacologyinstitute.com/section/rivalutazione-del-droperidolo-nella-gestione-dell-agitazione-it/ 2026-09-01T17:04:23+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-l-interazione-tra-antidepressivi-e-psicoterapia-it/ 2026-09-01T17:04:27+00:00 https://it.psychopharmacologyinstitute.com/section/sospensione-delle-benzodiazepine-e-dei-farmaci-z-nei-pazienti-anziani-ospedalizzati-it/ 2026-09-01T17:04:31+00:00 https://it.psychopharmacologyinstitute.com/section/anosmia-nei-pazienti-con-covid-19-impatto-e-potenziali-trattamenti-it/ 2026-09-01T17:04:35+00:00 https://it.psychopharmacologyinstitute.com/section/l-olanzapina-ad-alto-dosaggio-e-un-opzione-per-la-schizofrenia-resistente-al-trattamento-it/ 2026-09-01T17:04:39+00:00 https://it.psychopharmacologyinstitute.com/section/clozapina-e-sintomi-simil-ocd-qual-e-la-correlazione-it/ 2026-09-01T17:04:47+00:00 https://it.psychopharmacologyinstitute.com/section/l-aumento-di-peso-da-valproato-e-dose-dipendente-it/ 2026-09-01T17:04:51+00:00 https://it.psychopharmacologyinstitute.com/section/oltre-gli-antidepressivi-agonisti-della-dopamina-per-la-depressione-resistente-al-trattamento-it/ 2026-09-01T17:04:55+00:00 https://it.psychopharmacologyinstitute.com/section/il-delirium-aumenta-il-rischio-di-demenza-it/ 2026-09-01T17:04:59+00:00 https://it.psychopharmacologyinstitute.com/section/nuove-linee-guida-cliniche-per-il-trattamento-del-disturbo-da-uso-di-stimolanti-it/ 2026-09-01T17:05:03+00:00 https://it.psychopharmacologyinstitute.com/section/polmonite-nella-schizofrenia-quali-antipsicotici-comportano-il-rischio-maggiore-it/ 2026-09-01T17:05:10+00:00 https://it.psychopharmacologyinstitute.com/section/aumento-di-peso-indotto-dagli-antipsicotici-le-migliori-strategie-di-gestione-it/ 2026-09-01T17:05:14+00:00 https://it.psychopharmacologyinstitute.com/section/qual-e-il-range-terapeutico-ottimale-del-litio-nel-disturbo-bipolare-it/ 2026-09-01T17:05:18+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-vitamine-del-gruppo-b-e-cognizione-esiste-una-correlazione-it/ 2026-09-01T17:05:22+00:00 https://it.psychopharmacologyinstitute.com/section/gli-effetti-antidepressivi-dell-esercizio-fisico-un-framework-proposto-it/ 2026-09-01T17:05:26+00:00 https://it.psychopharmacologyinstitute.com/section/gli-agonisti-del-glp-1-possono-trattare-il-disturbo-da-uso-di-alcol-it/ 2026-09-01T17:05:34+00:00 https://it.psychopharmacologyinstitute.com/section/quali-antidepressivi-causano-il-maggior-aumento-di-peso-it/ 2026-09-01T17:05:37+00:00 https://it.psychopharmacologyinstitute.com/section/gli-antidepressivi-aumentano-il-rischio-di-cadute-negli-anziani-it/ 2026-09-01T17:05:41+00:00 https://it.psychopharmacologyinstitute.com/section/ketamina-ed-esketamina-nella-depressione-bipolare-it/ 2026-09-01T17:05:45+00:00 https://it.psychopharmacologyinstitute.com/section/l-aripiprazolo-e-davvero-piu-sicuro-dell-olanzapina-sul-piano-metabolico-it/ 2026-09-01T17:05:49+00:00 https://it.psychopharmacologyinstitute.com/section/antipsicotici-a-lunga-durata-d-azione-iniettabili-superiori-nella-riduzione-della-mortalita-nella-schizofrenia-it/ 2026-09-01T17:05:57+00:00 https://it.psychopharmacologyinstitute.com/section/mantenimento-nel-disturbo-bipolare-qual-e-il-range-posologico-ottimale-it/ 2026-09-01T17:06:01+00:00 https://it.psychopharmacologyinstitute.com/section/malattia-di-alzheimer-olanzapina-vs-risperidone-per-i-bpsd-it/ 2026-09-01T17:06:05+00:00 https://it.psychopharmacologyinstitute.com/section/la-lisdexamfetamina-puo-trattare-il-disturbo-da-uso-di-metanfetamina-it/ 2026-09-01T17:06:09+00:00 https://it.psychopharmacologyinstitute.com/section/cronoterapia-i-ritmi-circadiani-possono-influenzare-l-efficacia-del-trattamento-it/ 2026-09-01T17:06:14+00:00 https://it.psychopharmacologyinstitute.com/section/lurasidone-per-la-depressione-bipolare-qual-e-il-dosaggio-ottimale-it/ 2026-09-01T17:06:22+00:00 https://it.psychopharmacologyinstitute.com/section/disturbo-da-uso-di-alcol-il-disulfiram-dovrebbe-essere-di-prima-linea-it/ 2026-09-01T17:06:26+00:00 https://it.psychopharmacologyinstitute.com/section/melatonina-trazodone-o-doxepina-per-i-disturbi-del-sonno-it/ 2026-09-01T17:06:30+00:00 https://it.psychopharmacologyinstitute.com/section/avvertenze-degli-antipsicotici-sul-qt-riflettono-il-vero-rischio-cardiaco-it/ 2026-09-01T17:06:33+00:00 https://it.psychopharmacologyinstitute.com/section/stiamo-sopravvalutando-o-sottoutilizzando-la-clozapina-in-psichiatria-clozapina-versus-antipsicotici-di-seconda-generazione-nella-schizofrenia-resistente-al-trattamento-it/ 2026-09-01T17:06:37+00:00 https://it.psychopharmacologyinstitute.com/section/algoritmo-per-la-schizofrenia-selezione-di-un-antipsicotico-per-i-primi-episodi-it/ 2026-09-01T17:06:45+00:00 https://it.psychopharmacologyinstitute.com/section/gli-effetti-collaterali-degli-ssri-migliorano-nel-tempo-it/ 2026-09-01T17:06:49+00:00 https://it.psychopharmacologyinstitute.com/section/torsades-de-pointes-impatto-di-antidepressivi-e-antipsicotici-it/ 2026-09-01T17:06:53+00:00 https://it.psychopharmacologyinstitute.com/section/gli-psichedelici-sono-efficaci-nel-trattamento-dei-disturbi-da-uso-di-sostanze-it/ 2026-09-01T17:06:57+00:00 https://it.psychopharmacologyinstitute.com/section/le-neuroscienze-alla-base-degli-effetti-del-te-sulla-salute-mentale-it/ 2026-09-01T17:07:01+00:00 https://it.psychopharmacologyinstitute.com/section/lumateperone-per-la-depressione-con-caratteristiche-miste-e-efficace-it/ 2026-09-01T17:07:09+00:00 https://it.psychopharmacologyinstitute.com/section/aumento-di-peso-indotto-dagli-antipsicotici-gli-agonisti-del-glp-1-sono-efficaci-it/ 2026-09-01T17:07:13+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-resistente-al-trattamento-litio-vs-quetiapina-per-l-augmentation-it/ 2026-09-01T17:07:17+00:00 https://it.psychopharmacologyinstitute.com/section/gli-antidepressivi-peggiorano-la-cognizione-nei-pazienti-con-demenza-it/ 2026-09-01T17:07:21+00:00 https://it.psychopharmacologyinstitute.com/section/probiotici-e-prebiotici-per-la-depressione-e-l-ansia-puo-l-intestino-guarire-la-mente-it/ 2026-09-01T17:07:25+00:00 https://it.psychopharmacologyinstitute.com/section/integrate-nuove-linee-guida-per-il-trattamento-della-schizofrenia-it/ 2026-09-01T17:07:32+00:00 https://it.psychopharmacologyinstitute.com/section/la-lurasidone-e-efficace-nella-depressione-bipolare-con-ansia-in-comorbilita-it/ 2026-09-01T17:07:36+00:00 https://it.psychopharmacologyinstitute.com/section/gli-ssri-aumentano-il-rischio-di-sanguinamento-maggiore-con-gli-anticoagulanti-orali-it/ 2026-09-01T17:07:40+00:00 https://it.psychopharmacologyinstitute.com/section/sertralina-nei-pazienti-con-malattia-cardiovascolare-cosa-devono-sapere-gli-psichiatri-it/ 2026-09-01T17:07:43+00:00 https://it.psychopharmacologyinstitute.com/section/un-elevato-apporto-di-sale-aumenta-il-rischio-di-depressione-e-ansia-it/ 2026-09-01T17:07:47+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-bipolare-resistente-al-trattamento-il-pramipexolo-come-terapia-aggiuntiva-e-un-opzione-it/ 2026-09-01T17:07:55+00:00 https://it.psychopharmacologyinstitute.com/section/il-semaglutide-inverte-l-aumento-di-peso-indotto-dalla-clozapina-nella-schizofrenia-risultati-del-trial-coast-it/ 2026-09-01T17:07:59+00:00 https://it.psychopharmacologyinstitute.com/section/psicosi-indotta-da-cannabis-quali-antipsicotici-riducono-meglio-i-ricoveri-ospedalieri-it/ 2026-09-01T17:08:03+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-resistente-al-trattamento-quali-terapie-sono-piu-efficaci-una-network-meta-analisi-it/ 2026-09-01T17:08:08+00:00 https://it.psychopharmacologyinstitute.com/section/il-microbiota-intestinale-e-alterato-nella-depressione-e-nell-ansia-it/ 2026-09-01T17:08:12+00:00 https://it.psychopharmacologyinstitute.com/section/nuove-linee-guida-per-il-monitoraggio-dell-anc-in-corso-di-terapia-con-clozapina-it/ 2026-09-01T17:08:20+00:00 https://it.psychopharmacologyinstitute.com/section/dosaggio-della-cariprazina-per-il-disturbo-bipolare-negli-anziani-it/ 2026-09-01T17:08:25+00:00 https://it.psychopharmacologyinstitute.com/section/semaglutide-per-il-disturbo-da-uso-di-alcol-nuovi-dati-da-rct-it/ 2026-09-01T17:08:29+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-geriatrica-ottimizzazione-delle-strategie-e-sfide-comuni-it/ 2026-09-01T17:08:33+00:00 https://it.psychopharmacologyinstitute.com/section/lo-zafferano-e-efficace-quanto-gli-ssri-per-la-depressione-e-l-ansia-nuova-meta-analisi-it/ 2026-09-01T17:08:37+00:00 https://it.psychopharmacologyinstitute.com/section/quanto-e-efficace-karxt-xanomeline-trospium-nella-schizofrenia-nnt-e-nnh-spiegati-it/ 2026-09-01T17:08:45+00:00 https://it.psychopharmacologyinstitute.com/section/fototerapia-a-luce-intensa-per-la-depressione-bipolare-raccomandazioni-cliniche-isbd-it/ 2026-09-01T17:08:48+00:00 https://it.psychopharmacologyinstitute.com/section/aloperidolo-iv-i-timori-sulla-sicurezza-cardiaca-sono-eccessivi-it/ 2026-09-01T17:08:53+00:00 https://it.psychopharmacologyinstitute.com/section/vareniclina-e-bupropione-efficaci-nel-trattamento-del-disturbo-da-uso-di-alcol-it/ 2026-09-01T17:08:57+00:00 https://it.psychopharmacologyinstitute.com/section/l-ashwagandha-e-efficace-nel-deterioramento-cognitivo-lieve-it/ 2026-09-01T17:09:01+00:00 https://it.psychopharmacologyinstitute.com/section/l-ondansetron-e-efficace-per-i-sintomi-negativi-nella-schizofrenia-it/ 2026-09-01T17:09:09+00:00 https://it.psychopharmacologyinstitute.com/section/litio-orotato-trattamento-rivoluzionario-per-la-malattia-di-alzheimer-it/ 2026-09-01T17:09:13+00:00 https://it.psychopharmacologyinstitute.com/section/possiamo-prevedere-chi-risponde-agli-stabilizzatori-dell-umore-it/ 2026-09-01T17:09:17+00:00 https://it.psychopharmacologyinstitute.com/section/l-augmentazione-degli-ssri-e-superiore-all-ottimizzazione-della-dose-it/ 2026-09-01T17:09:20+00:00 https://it.psychopharmacologyinstitute.com/section/il-trazodone-e-sicuro-per-l-insonnia-nei-pazienti-con-disturbo-da-uso-di-alcol-it/ 2026-09-01T17:09:24+00:00 https://it.psychopharmacologyinstitute.com/section/passaggio-tra-antipsicotici-orali-sei-strategie-e-consigli-pratici-it/ 2026-09-01T17:09:31+00:00 https://it.psychopharmacologyinstitute.com/section/deprescrizione-degli-antipsicotici-dopo-il-delirium-perche-e-importante-it/ 2026-09-01T17:09:35+00:00 https://it.psychopharmacologyinstitute.com/section/overdose-da-xilazina-tranq-dope-cio-che-i-clinici-devono-sapere-it/ 2026-09-01T17:09:39+00:00 https://it.psychopharmacologyinstitute.com/section/il-pramipexolo-e-efficace-nel-trattamento-della-depressione-resistente-al-trattamento-it/ 2026-09-01T17:09:43+00:00 https://it.psychopharmacologyinstitute.com/section/i-farmaci-generici-sono-davvero-intercambiabili-con-gli-originali-it/ 2026-09-01T17:09:47+00:00 https://it.psychopharmacologyinstitute.com/section/schizofrenia-resistente-al-trattamento-considerare-olanzapina-ad-alto-dosaggio-invece-di-clozapina-it/ 2026-09-01T17:09:54+00:00 https://it.psychopharmacologyinstitute.com/section/potenziamento-vs-switch-dell-antidepressivo-nella-depressione-geriatrica-principali-risultati-del-trial-optimum-it/ 2026-09-01T17:09:58+00:00 https://it.psychopharmacologyinstitute.com/section/gli-agonisti-del-glp-1-possono-aumentare-i-livelli-di-litio-it/ 2026-09-01T17:10:02+00:00 https://it.psychopharmacologyinstitute.com/section/i-marcatori-infiammatori-possono-guidare-la-scelta-del-trattamento-antidepressivo-it/ 2026-09-01T17:10:06+00:00 https://it.psychopharmacologyinstitute.com/section/disturbo-di-panico-il-propranololo-e-utile-per-i-sintomi-somatici-precoci-it/ 2026-09-01T17:10:11+00:00 https://it.psychopharmacologyinstitute.com/section/riduzione-graduale-delle-benzodiazepine-punti-chiave-delle-nuove-linee-guida-it/ 2026-09-01T17:10:18+00:00 https://it.psychopharmacologyinstitute.com/section/glp-1-nella-schizofrenia-dobbiamo-prescrivere-semaglutide-per-la-gestione-metabolica-it/ 2026-09-01T17:10:22+00:00 https://it.psychopharmacologyinstitute.com/section/acido-eicosapentaenoico-efficace-come-terapia-aggiuntiva-nella-trd-it/ 2026-09-01T17:10:27+00:00 https://it.psychopharmacologyinstitute.com/section/diete-chetogeniche-in-psichiatria-risultati-di-una-nuova-meta-analisi-it/ 2026-09-01T17:10:31+00:00 https://it.psychopharmacologyinstitute.com/section/confronto-tra-strategie-di-deprescrizione-degli-antidepressivi-nuovi-risultati-da-una-meta-analisi-it/ 2026-09-01T17:10:34+00:00 https://it.psychopharmacologyinstitute.com/section/xanomeline-trospium-a-lungo-termine-efficacia-e-sicurezza-si-mantengono-dopo-un-anno-it/ 2026-09-01T17:10:42+00:00 https://it.psychopharmacologyinstitute.com/section/trazodone-per-l-insonnia-e-la-depressione-in-comorbidita-le-linee-guida-aasm-sono-pertinenti-it/ 2026-09-01T17:10:46+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-nel-disturbo-bipolare-meno-rischiosi-di-quanto-si-pensasse-quando-i-nuovi-dati-sfidano-le-certezze-consolidate-it/ 2026-09-01T17:10:50+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-nell-anziano-focus-sull-infiammazione-it/ 2026-09-01T17:10:54+00:00 https://it.psychopharmacologyinstitute.com/section/quanto-e-comune-l-abuso-e-la-diversione-di-stimolanti-nei-pazienti-con-adhd-it/ 2026-09-01T17:10:59+00:00 https://it.psychopharmacologyinstitute.com/section/i-farmaci-z-sono-sicuri-nel-primo-trimestre-di-gravidanza-it/ 2026-09-01T17:11:07+00:00 https://it.psychopharmacologyinstitute.com/section/declino-renale-da-litio-gli-inibitori-sglt2-possono-essere-d-aiuto-it/ 2026-09-01T17:11:11+00:00 https://it.psychopharmacologyinstitute.com/section/schizofrenia-quale-dei-sette-antipsicotici-primeggia-per-efficacia-acuta-e-sicurezza-it/ 2026-09-01T17:11:14+00:00 https://it.psychopharmacologyinstitute.com/section/depressione-lieve-gli-integratori-e-i-fitoterapici-sono-opzioni-ragionevoli-di-prima-linea-it/ 2026-09-01T17:11:18+00:00 https://it.psychopharmacologyinstitute.com/section/psicosi-indotta-da-sostanze-chi-rimane-in-terapia-antipsicotica-a-lungo-termine-it/ 2026-09-01T17:11:22+00:00 https://it.psychopharmacologyinstitute.com/section/psicosi-al-primo-episodio-nelle-donne-qual-e-l-antipsicotico-di-scelta-it/ 2026-09-01T17:11:30+00:00 https://it.psychopharmacologyinstitute.com/section/schizofrenia-resistente-al-trattamento-cosa-funziona-quando-la-clozapina-non-e-un-opzione-it/ 2026-09-01T17:11:33+00:00 https://it.psychopharmacologyinstitute.com/section/farmaci-per-l-insonnia-quale-e-il-loro-reale-rischio-di-abuso-nella-pratica-clinica-it/ 2026-09-01T17:11:37+00:00 https://it.psychopharmacologyinstitute.com/section/ketamina-e-superiore-al-midazolam-per-la-depressione-it/ 2026-09-01T17:11:41+00:00 https://it.psychopharmacologyinstitute.com/section/antocianine-e-funzione-cognitiva-cosa-dice-l-evidenza-it/ 2026-09-01T17:11:45+00:00 https://it.psychopharmacologyinstitute.com/section/catatonia-gli-antipsicotici-devono-essere-sempre-evitati-it/ 2026-09-01T17:11:52+00:00 https://it.psychopharmacologyinstitute.com/section/antidepressivi-nella-depressione-bipolare-affrontare-la-controversia-it/ 2026-09-01T17:11:56+00:00 https://it.psychopharmacologyinstitute.com/section/dovremmo-iniziare-la-clozapina-dopo-un-solo-fallimento-antipsicotico-it/ 2026-09-01T17:12:00+00:00 https://it.psychopharmacologyinstitute.com/section/il-consumo-di-bevande-gassate-e-associato-al-disturbo-depressivo-maggiore-it/ 2026-09-01T17:12:04+00:00 https://it.psychopharmacologyinstitute.com/section/la-depressione-atipica-e-un-sottotipo-clinico-distinto-it/ 2026-09-01T17:12:09+00:00 https://it.psychopharmacologyinstitute.com/section/catatonia-gli-antipsicotici-possono-prevenire-le-recidive-it/ 2026-09-01T17:12:18+00:00 https://it.psychopharmacologyinstitute.com/section/quale-antipsicotico-aggiuntivo-e-il-migliore-per-la-depressione-maggiore-it/ 2026-09-01T17:12:22+00:00 https://it.psychopharmacologyinstitute.com/section/schizofrenia-acuta-quali-antipsicotici-sono-piu-efficaci-e-meglio-tollerati-it/ 2026-09-01T17:12:26+00:00 https://it.psychopharmacologyinstitute.com/section/qual-e-l-effetto-degli-agonisti-del-recettore-glp-1-sull-ansia-it/ 2026-09-01T17:12:30+00:00 https://it.psychopharmacologyinstitute.com/section/quali-trattamenti-aiutano-realmente-i-pazienti-a-smettere-di-svapare-it/ 2026-09-01T17:12:34+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-i-livelli-di-evidenza-e-le-linee-di-trattamento-canmat-per-la-depressione-it/ 2026-09-01T17:13:06+00:00 https://it.psychopharmacologyinstitute.com/section/processo-decisionale-condiviso-nel-trattamento-della-depressione-it/ 2026-09-01T17:13:11+00:00 https://it.psychopharmacologyinstitute.com/section/selezione-del-trattamento-iniziale-per-la-depressione-it/ 2026-09-01T17:13:15+00:00 https://it.psychopharmacologyinstitute.com/section/medicina-complementare-e-alternativa-per-la-depressione-raccomandazioni-canmat-it/ 2026-09-01T17:13:20+00:00 https://it.psychopharmacologyinstitute.com/section/terapia-di-mantenimento-per-la-prevenzione-della-depressione-it/ 2026-09-01T17:13:24+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-della-depressione-difficile-da-trattare-it/ 2026-09-01T17:13:28+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-farmacologica-della-depressione-difficile-da-trattare-opzioni-di-prima-seconda-e-terza-linea-it/ 2026-09-01T17:13:32+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-di-neurostimolazione-per-la-gestione-della-depressione-difficile-da-trattare-it/ 2026-09-01T17:13:36+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-collaborare-con-i-pazienti-per-ottimizzare-il-trattamento-it/ 2026-09-01T17:13:40+00:00 https://it.psychopharmacologyinstitute.com/section/linee-guida-canmat-sulla-depressione-punti-chiave-it/ 2026-09-01T17:13:44+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-il-dolore-nellosteoartrite-e-nella-fibromialgia/ 2026-09-01T17:13:52+00:00 https://it.psychopharmacologyinstitute.com/section/caratterizzazione-meccanicistica-del-dolore-2/ 2026-09-01T17:13:56+00:00 https://it.psychopharmacologyinstitute.com/section/diagnosticare-la-fibromialgia/ 2026-09-01T17:14:00+00:00 https://it.psychopharmacologyinstitute.com/section/dolore-centralizzato-in-condizioni-di-dolore-cronico/ 2026-09-01T17:14:04+00:00 https://it.psychopharmacologyinstitute.com/section/fisiopatologia-e-neuroimaging-degli-stati-di-dolore-centralizzato/ 2026-09-01T17:14:07+00:00 https://it.psychopharmacologyinstitute.com/section/terapie-farmacologiche-per-la-fibromialgia-2/ 2026-09-01T17:14:11+00:00 https://it.psychopharmacologyinstitute.com/section/fibromialgia-e-cannabis-terapeutica-2/ 2026-09-01T17:14:15+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-del-dolore-personalizzati-in-base-ai-meccanismi-sottostanti/ 2026-09-01T17:14:18+00:00 https://it.psychopharmacologyinstitute.com/section/terapie-non-farmacologiche-per-la-fibromialgia/ 2026-09-01T17:14:22+00:00 https://it.psychopharmacologyinstitute.com/section/strategie-di-colloquio-motivazionale-per-i-consumatori-di-benzodiazepine/ 2026-09-01T17:14:33+00:00 https://it.psychopharmacologyinstitute.com/section/deprescrizione-di-benzodiazepine-indicazioni-benefici-e-rischi/ 2026-09-01T17:14:37+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-i-principi-del-tapering-delle-benzodiazepine-2/ 2026-09-01T17:14:41+00:00 https://it.psychopharmacologyinstitute.com/section/tecniche-per-il-successo-del-tapering-delle-benzodiazepine/ 2026-09-01T17:14:46+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-e-gestire-i-sintomi-di-astinenza-da-benzodiazepine/ 2026-09-01T17:14:50+00:00 https://it.psychopharmacologyinstitute.com/section/esplorare-le-complessita-della-disfunzione-neurologica-indotta-dalle-benzodiazepine-bind-2/ 2026-09-01T17:14:54+00:00 https://it.psychopharmacologyinstitute.com/section/oltre-la-sospensione-delle-benzodiazepine-comprensione-degli-effetti-sulla-vita-e-strategie-di-supporto/ 2026-09-01T17:14:58+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-11/ 2026-09-01T17:15:03+00:00 https://it.psychopharmacologyinstitute.com/section/gestione-del-disturbo-bipolare-in-gravidanza-dilemmi-di-trattamento/ 2026-09-01T17:15:11+00:00 https://it.psychopharmacologyinstitute.com/section/impatto-della-sospensione-degli-stabilizzatori-dellumore-in-gravidanza/ 2026-09-01T17:15:15+00:00 https://it.psychopharmacologyinstitute.com/section/rischi-delluso-del-litio-in-gravidanza/ 2026-09-01T17:15:18+00:00 https://it.psychopharmacologyinstitute.com/section/disturbo-bipolare-in-gravidanza-gestione-del-litio/ 2026-09-01T17:15:22+00:00 https://it.psychopharmacologyinstitute.com/section/rischi-delluso-del-valproato-in-gravidanza-2/ 2026-09-01T17:15:27+00:00 https://it.psychopharmacologyinstitute.com/section/rischi-delluso-di-carbamazepina-e-lamotrigina-in-gravidanza/ 2026-09-01T17:15:32+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-sulla-funzione-cognitiva-e-sui-difetti-del-tubo-neurale-associati-allesposizione-fetale-agli-aed/ 2026-09-01T17:15:36+00:00 https://it.psychopharmacologyinstitute.com/section/rischi-delluso-di-antipsicotici-durante-la-gravidanza/ 2026-09-01T17:15:41+00:00 https://it.psychopharmacologyinstitute.com/section/rischi-delluso-di-gabapentin-e-topiramato-in-gravidanza-2/ 2026-09-01T17:15:45+00:00 https://it.psychopharmacologyinstitute.com/section/principi-guida-per-il-trattamento-del-disturbo-bipolare-in-gravidanza/ 2026-09-01T17:15:50+00:00 https://it.psychopharmacologyinstitute.com/section/vignetta-clinica-una-donna-con-disturbo-bipolare-che-desidera-una-gravidanza/ 2026-09-01T17:15:54+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-2-4/ 2026-09-01T17:15:59+00:00 https://it.psychopharmacologyinstitute.com/section/il-ruolo-degli-antipsicotici-a-rilascio-prolungato-iniettabili-nel-trattamento-della-schizofrenia-it/ 2026-09-01T17:16:07+00:00 https://it.psychopharmacologyinstitute.com/section/quando-prescrivere-gli-antipsicotici-lai-indicazioni-cliniche-it/ 2026-09-01T17:16:12+00:00 https://it.psychopharmacologyinstitute.com/section/perche-scegliere-i-lai-benefici-nella-schizofrenia-it/ 2026-09-01T17:16:16+00:00 https://it.psychopharmacologyinstitute.com/section/bilanciamento-dei-rischi-sfide-del-trattamento-con-lai-it/ 2026-09-01T17:16:20+00:00 https://it.psychopharmacologyinstitute.com/section/guidare-la-conversazione-come-discutere-i-lai-con-i-pazienti-it/ 2026-09-01T17:16:24+00:00 https://it.psychopharmacologyinstitute.com/section/lai-nella-pratica-clinica-aloperidolo-e-flufenazina-it/ 2026-09-01T17:16:28+00:00 https://it.psychopharmacologyinstitute.com/section/lai-nella-pratica-clinica-aripiprazolo-e-olanzapina-it/ 2026-09-01T17:16:32+00:00 https://it.psychopharmacologyinstitute.com/section/lai-nella-pratica-clinica-paliperidone-e-risperidone-it/ 2026-09-01T17:16:37+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-it/ 2026-09-01T17:16:41+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-9010-it/ 2026-09-01T17:16:45+00:00 https://it.psychopharmacologyinstitute.com/section/gli-antidepressivi-in-gravidanza-aumentano-il-rischio-di-autismo-e-adhd-it/ 2026-09-09T02:02:00+00:00 https://it.psychopharmacologyinstitute.com/section/gli-ssri-aumentano-il-rischio-di-aritmia-e-morte-improvvisa-se-associati-agli-antipsicotici-it/ 2026-09-09T02:02:07+00:00 https://it.psychopharmacologyinstitute.com/section/reintroduzione-della-clozapina-dopo-neutropenia-controindicazione-assoluta-o-relativa-it/ 2026-09-09T02:02:12+00:00 https://it.psychopharmacologyinstitute.com/section/dovremmo-rinominare-la-schizofrenia-it/ 2026-09-09T02:02:17+00:00 https://it.psychopharmacologyinstitute.com/section/ashwagandha-e-melatonina-per-il-sonno-meglio-insieme-che-da-soli-it/ 2026-09-09T02:02:22+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-2-2/ 2026-09-10T06:43:21+00:00 https://it.psychopharmacologyinstitute.com/section/le-benzodiazepine-la-loro-storia/ 2026-09-10T19:09:40+00:00 https://it.psychopharmacologyinstitute.com/section/benzodiazepine-neurofarmacologia-e-sviluppo-della-tolleranza/ 2026-09-10T19:09:48+00:00 https://it.psychopharmacologyinstitute.com/section/uso-appropriato-delle-benzodiazepine-indicazioni-e-selezione-ottimale/ 2026-09-10T19:09:56+00:00 https://it.psychopharmacologyinstitute.com/section/rischi-delle-benzodiazepine-controindicazioni-ed-effetti-collaterali/ 2026-09-10T19:10:04+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-i-principali-rischi-delluso-di-benzodiazepine/ 2026-09-10T19:10:15+00:00 https://it.psychopharmacologyinstitute.com/section/la-crisi-delle-benzodiazepine-sovraprescrizione-dipendenza-fisica-abuso-e-dipendenza/ 2026-09-10T19:10:23+00:00 https://it.psychopharmacologyinstitute.com/section/disturbo-da-uso-di-benzodiazepine/ 2026-09-10T19:10:32+00:00 https://it.psychopharmacologyinstitute.com/section/conseguenze-delluso-di-benzodiazepine-in-popolazioni-ad-alto-rischio/ 2026-09-10T19:10:40+00:00 https://it.psychopharmacologyinstitute.com/section/conseguenze-delluso-di-benzodiazepine-in-gravidanza-allattamento-e-adolescenza/ 2026-09-10T19:10:48+00:00 https://it.psychopharmacologyinstitute.com/section/vignetta-clinica-strategie-per-un-uso-piu-sicuro-delle-benzodiazepine/ 2026-09-10T19:10:57+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-16/ 2026-09-10T19:11:06+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-cardiovascolari-degli-psicofarmaci-pressione-arteriosa-frequenza-cardiaca-e-rischio-emorragico-it/ 2026-09-10T19:11:42+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-cardiovascolari-degli-stimolanti-e-dei-farmaci-non-stimolanti-per-l-adhd-it/ 2026-09-10T19:11:54+00:00 https://it.psychopharmacologyinstitute.com/section/prolungamento-del-qt-con-gli-antipsicotici-stratificazione-del-rischio-e-monitoraggio-ecg-it/ 2026-09-10T19:12:04+00:00 https://it.psychopharmacologyinstitute.com/section/aloperidolo-iv-e-torsades-de-pointes-separare-il-mito-dall-evidenza-it/ 2026-09-10T19:12:13+00:00 https://it.psychopharmacologyinstitute.com/section/miocardite-e-cardiomiopatia-indotte-da-clozapina-riconoscimento-e-monitoraggio-it/ 2026-09-10T19:12:23+00:00 https://it.psychopharmacologyinstitute.com/section/prolungamento-del-qt-con-gli-antidepressivi-una-classificazione-del-rischio-it/ 2026-09-10T19:12:31+00:00 https://it.psychopharmacologyinstitute.com/section/effetti-cardiaci-del-litio-della-lamotrigina-e-di-altri-stabilizzatori-dell-umore-it/ 2026-09-10T19:12:41+00:00 https://it.psychopharmacologyinstitute.com/section/prolungamento-del-qt-con-metadone-donepezil-e-ibogaina-it/ 2026-09-10T19:12:49+00:00 https://it.psychopharmacologyinstitute.com/section/sette-falsi-miti-sul-qtc-e-i-farmaci-psichiatrici-it/ 2026-09-10T19:12:58+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-agitazione-e-qtc-prolungato-in-un-paziente-cardiologico-ad-alto-rischio-it/ 2026-09-10T19:13:07+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-chiave-11511-it/ 2026-09-10T19:13:16+00:00 https://it.psychopharmacologyinstitute.com/section/adhd-nelladulto-capire-la-prevalenza-la-persistenza-e-le-comorbidita/ 2026-09-10T19:16:23+00:00 https://it.psychopharmacologyinstitute.com/section/caso-di-adhd-per-adulti-il-signor-jones/ 2026-09-10T19:16:31+00:00 https://it.psychopharmacologyinstitute.com/section/screening-per-ladhd-cosa-devono-cercare-i-medici/ 2026-09-10T19:16:39+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-delladhd-nelladulto-colloquio-clinico-e-scale-di-valutazione/ 2026-09-10T19:16:47+00:00 https://it.psychopharmacologyinstitute.com/section/algoritmo-di-trattamento-per-ladhd-delladulto/ 2026-09-10T19:16:56+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-farmacologici-per-ladhd-nelladulto-focus-sugli-stimolanti/ 2026-09-10T19:17:04+00:00 https://it.psychopharmacologyinstitute.com/section/stimolanti-considerazioni-cliniche-prevenzione-dellabuso-e-segnali-di-allarme/ 2026-09-10T19:17:12+00:00 https://it.psychopharmacologyinstitute.com/section/trattamenti-non-stimolanti-per-ladhd-nelladulto/ 2026-09-10T19:17:20+00:00 https://it.psychopharmacologyinstitute.com/section/psicoterapia-approcci-psicosociali-e-neurofeedback-per-ladhd-delladulto/ 2026-09-10T19:17:28+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-17/ 2026-09-10T19:17:37+00:00 https://it.psychopharmacologyinstitute.com/section/psicosi-nelle-donne-lo-stato-ormonale-dovrebbe-influenzare-la-prescrizione-it/ 2026-09-10T19:18:04+00:00 https://it.psychopharmacologyinstitute.com/section/schizofrenia-il-semaglutide-supera-il-liraglutide-nel-controllo-dell-aumento-di-peso-da-antipsicotici-it/ 2026-09-10T19:18:12+00:00 https://it.psychopharmacologyinstitute.com/section/mantenimento-nel-disturbo-bipolare-classificazione-dei-farmaci-per-efficacia-nel-mondo-reale-it/ 2026-09-10T19:18:21+00:00 https://it.psychopharmacologyinstitute.com/section/il-litio-carbonato-a-basso-dosaggio-rallenta-il-declino-cognitivo-nel-deterioramento-cognitivo-lieve-it/ 2026-09-10T19:18:29+00:00 https://it.psychopharmacologyinstitute.com/section/terapia-chetogenica-nelle-malattie-mentali-gravi-consenso-di-esperti-it/ 2026-09-10T19:18:38+00:00 https://it.psychopharmacologyinstitute.com/section/comprendere-le-basi-della-tms/ 2026-09-10T19:19:14+00:00 https://it.psychopharmacologyinstitute.com/section/dispositivi-e-bobine-tms-approvati-dalla-fda/ 2026-09-10T19:19:23+00:00 https://it.psychopharmacologyinstitute.com/section/la-scienza-dietro-la-tms-i-circuiti-cerebrali/ 2026-09-10T19:19:31+00:00 https://it.psychopharmacologyinstitute.com/section/valutazione-dei-potenziali-effetti-collaterali-della-tms/ 2026-09-10T19:19:40+00:00 https://it.psychopharmacologyinstitute.com/section/esplorare-le-prove-della-tms-per-la-depressione/ 2026-09-10T19:19:48+00:00 https://it.psychopharmacologyinstitute.com/section/esplorare-le-prove-della-tms-per-il-doc/ 2026-09-10T19:19:57+00:00 https://it.psychopharmacologyinstitute.com/section/recenti-innovazioni-nella-ricerca-e-nella-pratica-della-tms/ 2026-09-10T19:20:06+00:00 https://it.psychopharmacologyinstitute.com/section/ottimizzazione-della-selezione-dei-pazienti-per-il-trattamento-tms/ 2026-09-10T19:20:15+00:00 https://it.psychopharmacologyinstitute.com/section/esplorare-altri-usi-della-tms/ 2026-09-10T19:20:25+00:00 https://it.psychopharmacologyinstitute.com/section/caso-clinico-2/ 2026-09-10T19:20:34+00:00 https://it.psychopharmacologyinstitute.com/section/messaggi-utili-15/ 2026-09-10T19:20:43+00:00